

1 **A genome-wide association study for nonalcoholic fatty liver disease**  
2 **identifies novel genetic loci and trait-relevant candidate genes in the**  
3 **Million Veteran Program.**

4 Marijana Vujkovic<sup>1\*</sup>, Shweta Ramdas<sup>2\*</sup>, Kimberly M. Lorenz<sup>1,2,3</sup>, Carolin V. Schneider<sup>2</sup>, Joseph  
5 Park<sup>2,4</sup>, Kyung M. Lee<sup>5</sup>, Marina Serper<sup>1</sup>, Rotonya M. Carr<sup>4</sup>, David E. Kaplan<sup>1</sup>, Mary E. Haas<sup>6</sup>,  
6 Matthew T. MacLean<sup>2</sup>, Walter R. Witschey<sup>7</sup>, Xiang Zhu<sup>8,9,10,11</sup>, Catherine Tcheandjieu<sup>11,12</sup>, Rachel  
7 L. Kember<sup>13,14</sup>, Henry R. Kranzler<sup>13,14</sup>, Anurag Verma<sup>1,2</sup>, Ayush Giri<sup>15</sup>, Derek M. Klarin<sup>16,17,18</sup>, Yan V.  
8 Sun<sup>19,20</sup>, Jie Huang<sup>21</sup>, Jennifer Huffman<sup>16</sup>, Kate Townsend Creasy<sup>2</sup>, Nicholas J. Hand<sup>2</sup>, Ching-Ti  
9 Liu<sup>22</sup>, Michelle T. Long<sup>23</sup>, Jerome I. Rotter<sup>24</sup>, Xiuqing Guo<sup>24</sup>, Jie Yao<sup>24</sup>, Matthew Budoff<sup>25</sup>, Katherine  
10 A. Ryan<sup>26</sup>, Braxton D. Mitchell<sup>27</sup>, Dipender Gill<sup>28</sup>, Andrew D. Wells<sup>29</sup>, Elisabetta Manduchi<sup>30</sup>,  
11 Yedidya Saiman<sup>31</sup>, Nadim Mahmud<sup>31</sup>, Donald R. Miller<sup>32,33</sup>, Peter D. Reaven<sup>34,35</sup>, Laurence S.  
12 Phillips<sup>19,36</sup>, Sumitra Muralidhar<sup>37</sup>, Scott L. DuVall<sup>5,38</sup>, Jennifer S. Lee<sup>11,12</sup>, Themistocles L.  
13 Assimes<sup>11,12</sup>, Saiju Pyarajan<sup>16,39,40</sup>, Kelly Cho<sup>16,39</sup>, Todd L. Edwards<sup>41,42</sup>, Scott M. Damrauer<sup>1,43</sup>,  
14 Peter W. Wilson<sup>19,44</sup>, John M. Gaziano<sup>16,39</sup>, Christopher J. O'Donnell<sup>16,39,40</sup>, Amit V. Khera<sup>17,18,40</sup>,  
15 Struan F.A. Grant<sup>45</sup>, Christopher D. Brown<sup>2</sup>, Philip S. Tsao<sup>11,12</sup>, Danish Saleheen<sup>46,47,48</sup>, James B.  
16 Meigs<sup>18,40,49</sup>, Julie A. Lynch<sup>5,38</sup>, Daniel J. Rader<sup>\*2,4</sup>, Benjamin F. Voight<sup>\*1,2,3,51</sup>, Kyong-Mi Chang<sup>1,3\*</sup>

17

18

19

20

21 \*These authors contributed equally

## 22 **Affiliations**

23 1. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA 2. Department of Genetics, University of  
24 Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 3. Department of Systems Pharmacology and  
25 Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 4.  
26 Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 5. VA Salt  
27 Lake City Health Care System, Salt Lake City, UT, USA 6. Broad Institute of MIT and Harvard, Cambridge, MA, USA 7.  
28 Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 8.  
29 Department of Statistics, The Pennsylvania State University, University Park, PA, USA 9. Huck Institutes of the Life  
30 Sciences, The Pennsylvania State University, University Park, PA, USA 10. Department of Statistics, Stanford  
31 University, Stanford, CA, USA 11. VA Palo Alto Health Care System, Palo Alto, CA, USA 12. Department of Medicine,  
32 Stanford University School of Medicine, Stanford, CA, USA 13. Mental Illness Research, Education and Clinical Center,  
33 Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA 14. Department of Psychiatry, University of  
34 Pennsylvania Perelman School of Medicine, Philadelphia PA, USA 15. Department of Obstetrics and Gynecology,  
35 Vanderbilt University Medical Center, Nashville TN, USA 16. VA Boston Healthcare System, Boston MA, USA 17.  
36 Center for Genomic Medicine, Massachusetts General Hospital, Boston MA, USA 18. Program in Medical and  
37 Population Genetics, Broad Institute of MIT and Harvard, Cambridge MA, USA 19. Atlanta VA Medical Center,  
38 Decatur GA, USA. 20. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta GA, USA  
39 21. Department of Global Health, School of Public Health, Peking University, Beijing, China. 22. Department of  
40 Biostatistics, Boston University School of Public Health, Boston, MA, USA 23. Department of Medicine, Section of  
41 Gastroenterology, Boston University School of Medicine, Boston, MA, USA 24. Department of Pediatrics, Genomic  
42 Outcomes, The Institute for Translational Genomics and Population Sciences, The Lundquist Institute for Biomedical  
43 Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA 25 Cardiology, The Lundquist Institute for Biomedical  
44 Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA 26 VISN 5 Capitol Health Care Network Mental Illness  
45 Research Education and Clinical Center, Baltimore, MD, USA 27 Program for Personalized and Genomic Medicine,  
46 Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of  
47 Medicine, Baltimore, MD, USA 28. Department of Epidemiology and Biostatistics, School of Public Health, Imperial

48 College London, London, UK. 29. Department of Pathology and Laboratory Medicine, University of Pennsylvania  
49 Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia PA, USA 30. Institute for  
50 Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia PA, USA. 31.  
51 Department of Medicine, Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine,  
52 Philadelphia PA, USA. 32. Edith Nourse Rogers Memorial VA Hospital, Bedford, MA, USA. 33. Center for Population  
53 Health, University of Massachusetts, Lowell, MA, USA. 34. Phoenix VA Health Care System, Phoenix, AZ, USA. 35.  
54 College of Medicine, University of Arizona, Tuscon, AZ, USA. 36. Division of Endocrinology, Emory University School  
55 of Medicine, Atlanta, GA, USA. 37. Office of Research and Development, Veterans Health Administration,  
56 Washington, DC, USA. 38. Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.  
57 39. Department of Medicine, Brigham Women's Hospital, Boston, MA, USA. 40. Department of Medicine, Harvard  
58 Medical School, Boston, MA, USA. 41. Nashville VA Medical Center, Nashville, TN, USA. 42. Vanderbilt Genetics  
59 Institute, Vanderbilt University Medical Center, Nashville, TN, USA. 43. Department of Surgery, University of  
60 Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 44. Division of Cardiology, Emory University  
61 School of Medicine, Atlanta GA, USA. 45. Department of Pediatrics, University of Pennsylvania Perelman School of  
62 Medicine and Children's Hospital of Philadelphia, Philadelphia, PA, USA. 46. Department of Medicine, Columbia  
63 University Irving Medical Center, New York, NY, USA. 47. Department of Cardiology, Columbia University Irving  
64 Medical Center, New York, NY, USA. 48. Center for Non-Communicable Diseases, Karachi, Sindh, Pakistan. 49.  
65 Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. 50. College of Nursing and  
66 Health Sciences, University of Massachusetts, Lowell, MA, USA. 51. Institute of Translational Medicine and  
67 Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

68  
69

70 **Abstract**

71 Nonalcoholic fatty liver disease (NAFLD) is a prevalent, heritable trait that can progress to cancer  
72 and liver failure. Using our recently developed proxy definition for NAFLD based on chronic liver  
73 enzyme elevation without other causes of liver disease or alcohol misuse, we performed a multi-  
74 ancestry genome-wide association study in the Million Veteran Program with 90,408 NAFLD  
75 cases and 128,187 controls. Seventy-seven loci exceeded genome-wide significance of which 70  
76 were novel, with an additional European-American specific and two African-American specific  
77 loci. Twelve of these loci were also significantly associated with quantitative hepatic fat on  
78 radiological imaging (n=44,289). Gene prioritization based on coding annotations, gene  
79 expression from GTEx, and functional genomic annotation identified candidate genes at 97% of  
80 loci. At eight loci, the allele associated with lower gene expression in liver was also associated  
81 with reduced risk of NAFLD, suggesting potential therapeutic relevance. Functional genomic  
82 annotation and gene-set enrichment demonstrated that associated loci were relevant to liver  
83 biology. We expand the catalog of genes influencing NAFLD, and provide a novel resource to  
84 understand its disease initiation, progression and therapy.

85

## 86 **Introduction**

87 Chronic liver disease is a major contributor to global morbidity and mortality, with complications  
88 of cirrhosis and hepatocellular carcinoma<sup>1</sup>. In particular, nonalcoholic fatty liver disease (NAFLD)  
89 is an increasingly common cause of chronic liver disease with an estimated world prevalence of  
90 25% among adults and associated metabolic risk factors<sup>1-5</sup>. In the United States (US), NAFLD  
91 prevalence is projected to reach 33.5% among adult population by 2030, due in large part to the  
92 rising obesity and associated metabolic disorders<sup>6</sup>. NAFLD is defined by  $\geq 5\%$  fat accumulation in  
93 the liver (hepatic steatosis) in the absence of other known causes for liver disease, based on liver  
94 biopsy and/or non-invasive radiological imaging<sup>3,4</sup>. The clinical spectrum of NAFLD ranges from  
95 benign steatosis to nonalcoholic steatohepatitis (NASH) involving inflammation and  
96 hepatocellular injury with fibrosis progression. At least 20% of patients with NAFLD develop NASH  
97 with increased risk of consequent cirrhosis and liver cancer<sup>5,6</sup>. To date, there is no licensed drug  
98 approved to treat NAFLD and prevent its progression.

99 Individual susceptibility to NAFLD involves both genetic and environmental factors. Risk  
100 factors for NAFLD include obesity (in particular, abdominal adiposity), insulin resistance and  
101 features of metabolic syndrome<sup>2,5-7</sup>, with current estimates of NAFLD heritability ranging  
102 between 20% to 50%<sup>8</sup>. Several genetic variants that promote the full spectrum of fatty liver  
103 disease have been identified in genome-wide association studies (GWAS) utilizing cohorts based  
104 on liver biopsy, imaging, and/or isolated liver enzyme values<sup>9-22</sup>. The most prominent of these  
105 include p.I148M in *PNPLA3* and p.E167K in *TM6SF2*, which increase NAFLD risk, and a loss-of-  
106 function variant in *HSD17B13* that confers protection against NASH<sup>16</sup>. However, the limited  
107 number of genetic associations in NAFLD contrasts with other cardiometabolic disorders where  
108 hundreds of loci have been mapped to date, traits that include obesity<sup>23,24</sup>, type 2 diabetes<sup>25</sup> and

109 plasma lipids<sup>26</sup>. This also highlights the need for expanded discovery based on larger sample size  
110 and population diversity, with further integration with existing functional genomics data sets to  
111 identify candidate genes from leading, non-coding associations<sup>27</sup>.

112 The Million Veteran Program (MVP) is among the world's largest and ancestrally diverse  
113 biobanks<sup>28</sup>. The availability of comprehensive, longitudinally collected Veterans Health  
114 Administration (VA) electronic health records for US Veteran participants in the MVP also makes  
115 it a promising resource for precision medicine. As NAFLD is markedly underdiagnosed clinically  
116 due to limited access to liver biopsy and variable use of imaging modalities<sup>4</sup>, we recently  
117 developed and validated a proxy phenotype for NAFLD to facilitate case identification in MVP<sup>21</sup>.  
118 The proxy NAFLD phenotype is based on chronically elevated serum alanine aminotransferase  
119 (cALT) levels while excluding other conditions that are known to increase liver enzymes (e.g. viral  
120 hepatitis, alcohol dependence, autoimmune liver disease and known hereditary liver disease).  
121 We applied this cALT-based proxy NAFLD phenotype to the current build of 430,400 genotyped  
122 MVP participants with defined ancestry classification<sup>29</sup>, and identified 90,408 NAFLD cases and  
123 128,187 controls (inclusion/exclusion criteria for the remaining samples and study design  
124 described in **Supplementary Figure 1** and **Figure 1**). We performed a primary GWAS and  
125 identified 77 trans-ancestry loci that reached genome-wide significance. We used additional  
126 approaches to define NAFLD heritability and genetic correlations with various traits including  
127 quantitative hepatic fat measured by liver imaging with computed tomography (CT) and magnetic  
128 resonance imaging (MRI), in addition to identifying coding variants in putative causal genes.

129

130

131 **Results**

132 *Diverse NAFLD case and control subjects enriched for metabolic disorders in MVP.*

133 Our study consisted of 90,408 NAFLD cases and 128,187 controls across two stages and  
134 comprising four ancestral groups, namely European Americans (EA, 75.1%), African Americans  
135 (AA, 17.1%), Hispanic-Americans (HISP, 6.9%), and Asian-Americans (ASN, 0.9%, **Supplemental**  
136 **Table 1**) with the overall sample sizes and study design shown in **Figure 1 and Supplemental**  
137 **Figure 1**. Consistent with the US Veteran population, MVP cases and controls (n = 218,595) were  
138 predominantly male (92.3%) with an average age of 64 years at study enrollment (**Supplemental**  
139 **Table 1**). With the exclusion of other known causes of liver disease in our phenotype definition<sup>21</sup>,  
140 our cohort was enriched for metabolic disorders, with higher prevalence in cases as compared to  
141 controls for type 2 diabetes (71% vs. 47%,  $P < 1 \times 10^{-5}$ ), hypertension (73% vs. 60%,  $P < 1 \times 10^{-5}$  and  
142 dyslipidemia (82% vs. 70%,  $P < 1 \times 10^{-5}$ ).

143

144 *Identification of novel trans-ancestry and ancestry-specific NAFLD-associated loci in the diverse*  
145 *MVP population*

146 To identify loci associated with NAFLD, we performed ancestry-specific genome-wide scans by  
147 meta-analyzing summary statistics derived from each ancestry followed by trans-ancestry meta-  
148 analysis combining data across all ancestries and stages (**Methods and Figure 1**). In the trans-  
149 ancestry scan across stages, 77 independent sentinel SNPs exceeded genome-wide significance  
150 ( $P < 5 \times 10^{-8}$ ), of which 70 were novel whereas 7 (namely *PNPLA3*, *TM6SF2*, *ERLIN1*, *TNKS*  
151 [*PPP1R3B*], *MARC1*, *HSD17B13*, and *LYPLAL1*) had previously reported genome-wide significant  
152 associations with NAFLD (within 500kb and/or CEU  $r^2$  LD > 0.05; **Figure 2 and Supplemental Table**

153 2)<sup>9-22</sup>. In addition, 55 loci in EAs, 8 loci in AAs, and 3 loci in HISPs, exceeded genome-wide  
154 significance (**Supplemental Tables 3-5** and **Supplemental Figures 2-4**). One SNP (*rs4940689*)  
155 reached genome-wide significance in an ancestry-specific analysis of EAs only (**Supplemental**  
156 **Table 3**), whereas two SNPs (*rs144127357*; *rs2666559*) reached genome-wide significance among  
157 AAs only (**Supplemental Table 4**). No loci in ASNs achieved genome-wide significance, likely due  
158 to limited sample size in this group (**Supplemental Figure 5**).

159         Among the eight AA-specific lead SNPs, three were intronic: *rs115038698* in the *ABCB4*  
160 locus, *rs144127357* in *TJP2*, and *rs2666559* in *NRXN2*. Two of these variants were nearly  
161 monomorphic in EA but polymorphic in AA (*rs115038698* MAF AA: 1.2%, MAF EA: 0%;  
162 *rs144127357* MAF AA: 3.14%, MAF EA: <0.001%). In contrast, the tagged variant *rs2666559* was  
163 common in both AA (MAF = 19.1% in AA, gnomAD AF = 17.2% in Africans) and EA (AF = 69.1% in  
164 EA, gnomAD AF = 68.4% in non-Finnish Europeans).

165

#### 166 *Internal and external replication of NAFLD-associated loci.*

167 We next compared the extent of association across both Stage 1 (primary analysis) and Stage 2  
168 replication stage internally in MVP and externally in the Penn Medicine Biobank (PMBB,  
169 **Methods**). Of the 77 associated SNPs from the trans-ancestry meta-analysis, 56 reached genome-  
170 wide significance in Stage 1 subset, of which 32 passed Bonferroni significance (0.05/56) in Stage  
171 2 replication in MVP (**Supplemental Table 2**). All 77 SNPs showed directional concordance in  
172 effect estimates between the two stages. External replication for our trans-ancestry lead SNPs in  
173 PMBB (n=72 of our loci were genotyped) with 2,570 cases and 3,802 controls demonstrated that  
174 8 out of 72 variants were directionally consistent and nominally associated (signed binomial-test



175  $P=4.4 \times 10^{-4}$ ). Furthermore, 4 out of 8 loci discovered in the AA-specific scan (signed binomial-  
176 test  $P=2.5 \times 10^{-5}$ ) and 1 of 3 loci discovered in the HISP-specific scan (signed binomial test  $P=0.07$ )  
177 were also directionally consistent and nominally associated in PMBB (**Supplemental Tables 6-9**).  
178 In summary, we found 73 novel loci associated with NAFLD that were identified by trans and  
179 single-ancestry association studies and supported by replication in multiple stages and studies.

180

### 181 *Concordance of cALT-based NAFLD loci with CT/MRI-based quantitative hepatic fat*

182 To place our discoveries into physiological context, we next investigated the extent to which the  
183 77 trans-ancestry SNPs from our NAFLD GWAS associated with quantitative measures of hepatic  
184 fat, derived from CT/MRI imaging studies (**Methods**). We performed a trans-ancestry meta-  
185 analysis among 44,289 participants in the UK Biobank, PMBB, Framingham Heart Study,  
186 University of Maryland Old Order Amish Study, and Multi-Ethnic Study of Atherosclerosis  
187 (**Supplemental Table 10**). We found that 24 SNPs were nominally associated with quantitative  
188 hepatic fat ( $P < 0.05$ ), of which 12 (15.6% of 77 loci) exceeded Bonferroni multi-test correction ( $P$   
189  $< 6.5 \times 10^{-4}$ , including *PNPLA3*, *TM6SF2*, *APOC1*; *APOE*, *GPAM*, *MARC1*, *KIAA0196* [*TRIB1*], *MTTP*,  
190 *APOH*, *PIK3R2*; *IFI30*; *MPV17L2*, *TNKS* [*PPP1R3B*], *COBLL1*; *SCN2A* and *PPARG*). Notably, *PNPLA3*,  
191 *TM6SF2*, and *TNKS* [*PPP1R3B*] were previously identified using imaging data<sup>11,12,14</sup>, and the  
192 direction of effect for all significant SNPs was concordant between chronic ALT elevation and  
193 hepatic fat, with the known exception of the variant at the *PPP1R3B* locus<sup>12</sup>.

194

### 195 *Identification of additional independent NAFLD-associated variants by conditional analysis*

196 To discover additional variants independent of our lead NAFLD signals, we next performed  
197 approximate conditional analysis using the leading sentinel variants at our 77 trans-ancestry  
198 associated loci. We detected a total of 41 conditionally independent SNPs flanking three known  
199 (*PNPLA3*, *HSD17B13*, and *ERLIN1*) and 17 novel NAFLD loci in EA (**Supplemental Table 11**). Nine  
200 conditionally independent SNPs were observed at the *PNPLA3* locus in MVP, indicative of the  
201 complexity of this locus. For one of the novel loci, located on chromosome 12 between 121-  
202 122Mb, the trans-ancestry lead variant (rs1626329) was located in *P2RX7*, whereas the lead peak  
203 for EA mapped to *HNF1A* (rs1169292, **Figure 3**). Both are strongly linked to distinct coding  
204 variants (*P2RX7*: rs1718119, Ala348Thr and *HNF1A*: rs1169288, Ile27Leu) and are compelling  
205 candidate genes for metabolic liver disease. In AA, we observed eight conditionally independent  
206 variants at four genomic loci, one at *PNPLA3* and three novel loci (**Supplemental Table 12**),  
207 including four in *GPT*, two in *AKNA*, one in *ABCB4*. In HISP, two conditionally independent variants  
208 in the *PNPLA3* locus were identified (**Supplemental Table 13**). Collectively, 51 additional variants  
209 were identified at 24 loci across ancestries based on conditional analysis.

210

#### 211 *Fine mapping to define potential causal variants in 95% credible sets*

212 To leverage increased sample size and population diversity to improve fine-mapping resolution,  
213 we computed 95% credible sets using Wakefield's approximate Bayes' factors<sup>30</sup> derived from the  
214 trans-ancestry meta-regression, EA, AA, and HISP scans (**Supplemental Table 14-17, Methods**).  
215 In a comparison of the trans-ancestry and EA-only scans, the trans-ancestry meta-regression  
216 reduced the median 95% credible set size from 9 (IQR 3 - 17) to 7.5 variants (IQR 2 - 13). A total  
217 of 11 distinct NAFLD associations were resolved to a single SNP in the trans-ancestry meta-

218 regression, with 4 additional loci suggestive a single SNP in the EA (n=2) and AA (n=2) ancestry-  
219 specific meta-analyses that were not already resolved to a single SNP via the trans-ancestry  
220 analysis.

221

222 *Heritability of NAFLD and genetic correlations with other phenotypes.*

223 To tabulate trait heritability and genetic correlation with others, we utilized LD score regression<sup>31-</sup>  
224 <sup>33</sup> (**Methods**). Consistent with our discovery of novel genetic associations, we estimated the SNP-  
225 based liability-scaled heritability at 16% (95% CI: 12-19,  $P < 1.0 \times 10^{-6}$ ) in EA. Genome-wide genetic  
226 correlations of NAFLD were calculated with a total of 774 complex traits and diseases by  
227 comparing allelic effects using LD score regression with the EA-specific NAFLD summary statistics.  
228 A total of 116 significant associations were observed (Bonferroni correction for 774 traits  $P <$   
229  $6.5 \times 10^{-5}$ , **Supplemental Table 18**). Consistent with the previous epidemiological associations with  
230 metabolic syndrome traits, we observed strong correlations with cardiometabolic risk factors  
231 including measures of obesity and adiposity, type 2 diabetes, hypertension, dyslipidemia,  
232 coronary artery disease, family history of metabolic risk factors and general health conditions in  
233 addition to educational attainment.

234

235 *Liver-specific enrichment of NAFLD heritability*

236 To ascertain the tissues contributing to the disease-association underlying NAFLD heritability, we  
237 performed tissue-specific analysis using stratified LD score regression. The strongest associations  
238 were observed in genomic annotations surveyed in liver, hepatocytes, adipose, and immune cell  
239 types among others (e.g., liver histone H3K36me3 and H3K4me1, adipose nuclei H3K27ac, spleen

240 TCR $\gamma\delta$ , eosinophils in visceral fat; **Supplemental Table 19**). Medical subject heading (MeSH)-  
241 based analysis showed enrichment mainly in hepatocytes and liver (False Discovery Rate (FDR) <  
242 5%, **Supplemental Table 20**). Gene set analysis showed strongest associations for liver and lipid-  
243 related traits (P-value <  $1 \times 10^{-6}$ , **Supplemental Table 21**). Enrichment analyses using publicly-  
244 available epigenomic data (implemented in GREGOR enrichment analysis, **Methods**) showed that  
245 most significant enrichments were observed for active enhancer chromatin state in liver,  
246 epigenetic modification of histone H3 in hepatocytes or liver-derived HepG2 cells (e.g. H3K27Ac,  
247 H3K9ac, H3K4me1, H3K4me3; **Supplemental Table 22 and 23**). These analysis support the  
248 hypothesis that our GWAS captures multiple physiological mechanisms that contribute  
249 heritability to NAFLD. Finally, DEPICT-based predicted gene function nominated gene candidates  
250 for 28 genes, including the known genes *PNPLA3* and *ERLIN1* (FDR <5%, **Supplemental Table 24**),  
251 as well as well-known cardiometabolic disease genes (e.g., *PPARG*).

252

253 *Coding variants in putative causal genes driving NAFLD associations.*

254 There were six novel trans-ancestry loci for which the lead SNP itself is a coding missense variant  
255 (**Supplementary Table 25**): Thr1412Asn in *CPS1* (rs1047891,  $\beta=0.037$ ,  $P=2.8 \times 10^{-8}$ ), Glu430Gln in  
256 *GPT* (rs141505249,  $\beta=-2.023$ ,  $P=9.0 \times 10^{-62}$ ), Val112Phe in *TRIM5* (rs11601507,  $\beta=0.099$ ,  $P=1.5 \times 10^{-14}$ ),  
257 Ala163Thr in *DNAJC22* (rs146774114,  $\beta=-0.157$ ,  $P=2.5 \times 10^{-8}$ ), Glu366Lys in *SERPINA1*  
258 (rs28929474,  $\beta=0.492$ ,  $P=9.01 \times 10^{-73}$ ) and Cys325Gly in *APOH* (rs1801689,  $\beta=0.17$ ,  $P=1.5 \times 10^{-18}$ ).

259 To identify additional coding variants that may drive the association between the lead SNPs and  
260 NAFLD risk, we investigated predicted loss of function (pLoF) and missense variants strongly  
261 linked to the identified NAFLD lead variants ( $r^2 > 0.7$ , **Supplemental Table 25-28**). Four previously

262 described missense variants were replicated in the current study, including Thr165Ala in *MARC1*,  
263 Ile292Val in *ERLIN1*, Glu167Lys in *TM6SF2* and Ile148Met in *PNPLA3*. Among novel loci, missense  
264 variants linked ( $r^2 > 0.7$ ) with lead variants included the genes *CCDC18*, *MERTK*, *APOL3*, *PPARG*,  
265 *MTTP*, *MLXIPL*, *ABCB4*, *AKNA*, *GPAM*, *SH2B3*, *P2RX7*, *NYNRIN*, *ANPEP*, *IFI30* and *MPV17L2*. Among  
266 the trans-ancestry coding missense variants, ten (*CCDC18*, *MLXIPL*, *ABCB4*, *AKNA*, *DNAJC22*,  
267 *SERPINA1*, *ANPEP*, *APOH*, *IFI30*, *MPV17L2*, and *PNPLA3*) were predicted based on two methods  
268 (SIFT, PolyPhen-2) to have potentially deleterious and/or damaging effects in protein  
269 function<sup>34,35</sup>. An AA-specific locus on chromosome (rs115038698, chr7:87024718) was strongly  
270 linked to a nearby missense variant Ala934Thr in *ABCB4* (rs61730509, AFR  $r^2=0.92$ ) with predicted  
271 deleterious effect, where the T-allele confers an increased risk of NAFLD ( $\beta=0.617$ ,  $P=1.8 \times 10^{-20}$ ).  
272 In summary, 24 of our 77 trans-ancestry loci prioritized a candidate gene based on a missense  
273 variant in tight linkage with the lead SNP (**Supplemental Table 25**).

274

#### 275 *Additional approaches to nominate putative causal genes*

276 We performed colocalization analyses with gene expression and splicing across 48 tissues  
277 measured by the GTEx project, and overlapped our lead SNPs with histone quantitative trait locus  
278 (QTL) data from livers to identify NAFLD-associated variants that are also associated with change  
279 in gene expression (eQTLs), splice isoforms (sQTLs), or histone modifications (hQTLs, **Methods**,  
280 **Supplemental Table 29**). Across all tissues, a total of 123 genes were prioritized with 20 genes in  
281 liver tissue (**Methods**). In liver tissue alone, a total of eight variant-gene pairs were identified  
282 where the allele associated with protection against NAFLD was also associated with reduced gene  
283 expression (i.e., the direction of effect was concordant between the GTEx eQTL and GWAS

284 sentinel variant): *AC091114.1*, *PANX1*, *FADS2*, *SHROOM3*, *U2SURP*, *NYNRIN*, *CD276* and *EFHD1*.  
285 Furthermore, sQTL analysis in GTEx v8 identified two genes in liver, *HSD17B13* and *ANPEP*, and  
286 12 genes (*MARC1*, *HSD17B13*, *ABO*, *FADS1-FADS2*, *TMEM258*, *MLXIP*, *ANPEP*, *KAT7*, *STRADA*,  
287 *DDX42*, *TRC4AP*, and *APOL3*) that were affected in at least two tissues (**Supplemental Table 30**).  
288 Finally, two of our lead SNPs were in high LD ( $r^2 > 0.8$ ) with variants that regulated H3K27ac levels  
289 in liver tissue (hQTLs), namely *EFHD1* (hQTL SNPs rs2140773, rs7604422 in *EFHD1*) and *FADS2*  
290 loci (hQTL rs174566 in *FADS2*)<sup>36</sup>.

291 We next mapped our NAFLD loci to regions of open chromatin using ATAC-seq in three  
292 biologically-relevant liver-derived tissues (human liver, liver cancer cell line [HepG2], and  
293 hepatocyte-like cells [HLC] derived from pluripotent stem cells)<sup>37</sup>. Additionally, we used  
294 promoter-focused Capture-C data to identify those credible sets that physically interact with  
295 genes in two relevant cell types (HepG2 and liver) (**Supplemental Table 31**). These datasets are  
296 useful entry points for deciphering regulatory mechanisms involved in the pathophysiology of  
297 NAFLD. Most notably, the genes *DHODH*, *H2AFZ*, *PAQR9*, *FTO*, *MIR644A*, *BCL7B* and *KRT82*  
298 showed interactions with NAFLD loci that were also in open chromatin in both HLC and HepG2  
299 cells.

300 Based on DEPICT gene prediction, coding variant linkage analysis, and QTL colocalization  
301 (**Supplemental Tables 24-31**), 215 potentially relevant genes for NAFLD were identified for the  
302 77 loci. A protein-protein interaction (PPI) analysis revealed that among the 192 available  
303 proteins, 86 nodes were observed, with a PPI enrichment ( $P < 9.0 \times 10^{-8}$ ) indicating that the  
304 network has substantially more interactions than expected by chance (**Supplemental Table 32**  
305 **and Supplemental Figure 6**).

306 For each gene identified from all of the above described analyses, we counted the number  
307 of times that the gene was identified for each of the analyses (DEPICT gene prediction, coding  
308 variant linkage, QTL colocalization, promotor Capture-C and/or ATAC-Seq peak overlap, and PPI  
309 network analysis) and divided this by the number of analyses (e.g., 8). We labeled this measure  
310 as the gene nomination score, which reflects the cumulative evidence supporting the respective  
311 gene as causal for the observed association. Based on our gene nomination scheme, we found  
312 evidence for a single gene nomination at 52 genomic loci, two genes at 14 loci, and three genes  
313 at six loci. Six loci had more than three genes nominated (one of which was HLA), and only two  
314 loci lacked any data to support a nomination (**Supplemental Table 33**). We further prioritized  
315 those loci which were prioritized by at least 3 sources of evidence (or 4 sources of evidence for  
316 coding variants). This resulted in a total of 27 loci supported by multiple lines of evidence (**Table**  
317 **1**), which included 6 loci with co-localizing eQTLs in liver or adipose tissues and connection to the  
318 predicted gene via Promoter CaptureC data (i.e., *EPHA2*, *IL1RN*, *SHROOM3*, *HKDC1*, *PANX1*,  
319 *DHODH*;HP).

320 Interestingly, 14 of the nominated genes are transcription factors (TF) (**Supplemental**  
321 **Table 34**). Of particular interest, two of these TFs have several downstream target genes  
322 identified using the DoRothEA data in OmniPath (**Methods**). Notably, the CEBPA TF targets the  
323 downstream genes *PPARG*, *TRIB1*, *GPAM*, *FTO*, *IRS1*, *CRIM1*, *HP*, *TBC1D8*, and *CPS1*, but also  
324 *NCEH1*, a gene in the vicinity of one of our associations that lacked a nominated candidate gene.  
325 Similarly, *HNF1A*, the lead gene in EA scan (and corresponding to the trans-ancestry *P2RX7* locus)  
326 targets *SLC2A2*, *MTTP*, and *APOH*.

327

328 *Polygenic Risk Score analyses.*

329 We calculated a candidate SNP polygenic risk score (PRS) based on Stage 1 350K dataset (primary  
330 set) to perform a PheWAS in an independent sample in MVP (Stage 2 replication set). We observed  
331 that an increased NAFLD PRS was associated with abnormal results of function study of liver  
332 (Bonferroni  $P < 3.1 \times 10^{-5}$ ), and showed suggestive significance with bacterial pneumonia, otalgia,  
333 gout and other crystal arthropathies and non-infectious gastroenteritis ( $P < 0.001$ , **Supplemental**  
334 **Table 35**). Furthermore, a NAFLD PRS based on the Stage 1 set was positively associated with  
335 NAFLD prediction in the Stage 2 replication set ( $P=3.8 \times 10^{-5}$ , **Supplemental Table 36**).

336

337 *Investigation of pleiotropy of lead NAFLD SNPs.*

338 We next sought to identify additional traits that were also associated with our 77 trans-ancestry  
339 lead SNPs. First, we performed a LabWAS of distinct clinical laboratory test results<sup>38</sup> in MVP  
340 (**Methods**), yielding 304 significant SNP-trait associations (**Supplemental Table 37, Supplemental**  
341 **Figure 7**). Second, we performed a PheWAS Analysis in UK Biobank data using SAIGE (**Methods**),  
342 which identified various SNP-trait associations that mapped to loci previously associated with  
343 liver traits, cardiometabolic traits, as well as additional enriched association for gallstones, gout,  
344 arthritis, and hernias (**Supplemental Tables 38 and 39**). In particular, we examined all  
345 associations for PheCode 571.5, “Other chronic nonalcoholic liver disease” which comprised  
346 1,664 cases and 400,055 controls. Of the  $n=73$  variants found, we noted that 14/73 were both  
347 nominally associated and directionally consistent with our scan (signed binomial test  $P=3.4 \times 10^{-9}$ ),  
348 providing additional validation for our scan (**Supplementary Table 40**). Third, we performed a  
349 SNP lookup using the curated data in the IEU OpenGWAS project (**Supplemental Tables 41 and**



350 **42)**, which identified 2,891 genome-wide significant SNP-trait associations for trans-ancestry  
351 SNPs, and additional 283 SNP-trait associations for the ancestry-specific lead SNPs. Finally, we  
352 performed cross-trait colocalization analyses using COLOC of EA, AA, and HISP lead loci with 36  
353 other GWAS statistics of cardiometabolic and blood cell related traits (**Methods**). This resulted in  
354 significant regional colocalization for 64 SNP-trait pairs in EA, 32 SNP-trait pairs in AA, and 12 SNP  
355 trait pairs in HISP (**Supplemental Table 43-45**).

356         Based on the four analyses described above, we categorized relevant phenotypes  
357 observed as liver traits, metabolic traits, or inflammatory traits based on all significant SNP-trait  
358 associations and their nominated candidate genes (**Supplemental Tables 37-44, Figure 4**). Across  
359 the trans-ancestry lead variants (n=77), ancestry-specific (n=3), and secondary proximal  
360 associations (*HNF1A*, n=1), 22 SNPs showed association with only liver traits (such as ALT, ALP,  
361 AST, and GGT) (**Figure 4**). By contrast, 23 loci showed associations with both liver and  
362 cardiometabolic traits (such as HDL, LDL, and total cholesterol, triglycerides, BMI, glucose, and  
363 HbA1c) whereas 3 loci (*IL1RN*, *TMEM147*; *ATP4A* and *RORA*) showed association with both liver  
364 traits and inflammatory traits (e.g., C-reactive protein, white blood cell count, lymphocyte count).  
365 Finally, 25 loci showed association with all three traits: liver, cardiometabolic, and inflammation.  
366 Notably, among 12 loci that showed significant association with hepatic fat (color-coded in red  
367 in **Figure 4**), 11 were associated with both liver and metabolic traits, including five that were also  
368 associated with inflammatory traits. Collectively, our findings identify novel NAFLD-associated  
369 genetic loci with pleotropic effects that may impact hepatic, metabolic and inflammatory traits.

370

371

## 372 Discussion

373 In this study, the largest and most diverse GWAS of NAFLD to date, we report a total of 77 trans-  
374 ancestry (of which 70 are novel) and 3 additional ancestry-specific loci that show significant  
375 genome-wide association with NAFLD. While our NAFLD definition is a proxy for chronic  
376 hepatocellular injury in the absence of other known causes of liver disease, we further used  
377 CT/MRI imaging data to compare to what extent these SNPs also associated with hepatic fat  
378 accumulation. Overall, 24 (~30%) of these loci were nominally associated with hepatic fat based  
379 on CT or MRI, and the majority of these overlapping SNPs were associated with metabolic and/or  
380 inflammatory traits. Thus, SNPs that are associated with liver enzymes, metabolic risk factors,  
381 and inflammatory biomarkers may be the most likely to be associated with liver steatosis and  
382 should be prioritized for further follow-up. Furthermore, detailed genetic correlation analyses  
383 showed significant enrichment of these SNPs for cardiometabolic traits, metabolic pathways, and  
384 genomic annotations relevant for NAFLD. We found that most of our index NAFLD-associated  
385 SNPs were associated with metabolic and/or inflammatory traits - the most common being lipid-  
386 related, followed by glycemic traits, hypertension, and cardiovascular disease, as well as  
387 cholelithiasis (gallstones), cholecystitis, osteoarthritis, hypothyroidism, and thrombophlebitis.  
388 Collectively, our findings offer a comprehensive and refined view of the genetic contribution to  
389 NAFLD with potential clinical, pathogenic, and therapeutic relevance. Integration of these with  
390 extant phenotypic association data sets allowed us to further characterize the functional  
391 mechanisms through which our identified loci may mediate NAFLD risk.

392 Previous studies for liver enzyme levels, particularly serum ALT activity, have been  
393 performed<sup>10,11,16</sup>. While there is overlap in the discoveries made by studies of natural variation

394 in circulating levels of this biomarker, our cohort and approach to phenotyping make our results  
395 and interpretation unique. First, the diversity of our cohort provides both additional power and  
396 potential for discovery, as the bulk of studies to date have been performed in predominantly  
397 European-ancestry cohorts. Second, our approach ascertains individuals with *chronic* elevation  
398 of this enzyme, consistent with genuine chronic liver disease. At the same time, we excluded  
399 individuals with known causes of liver disease outside of NAFLD via ICD code definition, which  
400 served to further enrich for metabolic disorders in our cohort. We further excluded control  
401 individuals who maybe have intermittent ALT elevation, focusing on a healthier, ‘super-control’  
402 subset of the population. The result is that our approach should have higher specificity to  
403 ascertained risk alleles that predispose to metabolic-induced fatty liver disease. In contrast, a  
404 standard-ALT scan would be powered to discover the full spectrum of causes of liver disease (and  
405 perhaps many more loci), many of which will not be specific to NAFLD and may be due to other  
406 causes. As we have shown in validation studies using quantitative measures of hepatic fat as well  
407 as ICD-code definitions of NAFLD, our results are highly directionally concordant, demonstrating  
408 the relevance of our proxy phenotype to liver disease and physiology. Genetic correlation analysis  
409 demonstrated strong correlation with cardiometabolic traits and disease, again consistent with  
410 the relevance of our trait relative to simple enzyme measures.

411       There are several aspects of our study that are worth highlighting. We demonstrate the  
412 strength of trans-ancestry GWAS for the discovery and interrogation of NAFLD susceptibility loci,  
413 discoveries made possible by the diversity and sample size of the Million Veteran Program cohort,  
414 of which 25% of participants are of non-European ancestry. Utilizing this data allows us to narrow  
415 down putatively causal variants through trans-ancestry fine-mapping and construction of

416 credible sets likely to harbor the likely culprit variant(s). Construction of credible sets using trans-  
417 ancestry data has been shown to facilitate fine-mapping by producing smaller credible sets  
418 compared to sets based on single ancestries<sup>39</sup>, an effect we also observed at our loci. Moreover,  
419 we identified eight NAFLD-associated loci in AAs. In particular, the lead SNP at the *ABCB4* locus  
420 (rs115038698) was in high LD with the missense variant rs61730509 (Ala934Thr, AFR  $r^2=0.92$ ) and  
421 segregated a very potent effect (OR=1.87, CI=1.64-2.14,  $P=1.8 \times 10^{-20}$ ). This variant is of low  
422 frequency in AA (MAF=1.2%) but virtually absent in EA and ASN. *ABCB4*, also known as multidrug  
423 resistance protein 3 (*MDR3*), is a compelling candidate gene, as it has been previously implicated  
424 in cholestasis, gallbladder disease, and adult biliary fibrosis/cirrhosis<sup>40-42</sup>. Finally, for a number of  
425 variant gene-pairs, the observed effect on NAFLD risk and the impact of gene expression in the  
426 liver was consistent with our understanding of the expected effect given what is known about  
427 gene function, suggesting possible relevance as therapeutic targets. Among those, genetic  
428 deletion of Pannexin 1 (encoded by *PANX1*) was reported to have a protective effect in mouse  
429 model of acute and chronic liver disease<sup>43,44</sup>, and is consistent with the data we report here.

430 Twelve of our loci were associated with quantitative measures of hepatic fat after  
431 multiple-test correction. These included loci previously associated with NAFLD or all-cause  
432 cirrhosis (e.g., *PNPLA3*, *TM6SF2*, *TNKS [PPP1R3B]*, *KIAA0196 [TRIB1]*, and *MARC1*), but also  
433 included novel loci reported here (e.g., *GPAM*, *APOE;APOC1*, *MTTP*, *APOH*, *IFI30;MPV17L2*,  
434 *SCN2A;COBLL1*, and *PPARG*). In all cases except *TNKS [PPP1R3B]*, the directional effect on hepatic  
435 fat was consistent with cALT levels. A discordance between measures of hepatic fat based on  
436 radiological and histological evaluation has been noted<sup>12</sup> and may be explained by the role of the

437 *PPP1R3B*-encoded protein in promoting the accumulation of hepatic glycogen<sup>45</sup> which may  
438 influence the contrast in hepatic images<sup>46,47</sup>.

439 Through functional genomic and bioinformatics prioritization analyses beyond those  
440 based on coding variants or eQTLs, we were able to nominate loci that have at least one  
441 candidate gene nominations at 75 out of our 77 (97%) identified loci. We found that these genes  
442 were often highly expressed in liver and have prior biological connections to liver physiology and  
443 disease, making this list compelling for further interrogation. As an example, *GPAM*, tagged by  
444 the missense variant rs2792751 (Ile43Val, EA  $r^2 = 0.99$ ), encodes the mitochondrial glycerol-3-  
445 phosphate-acyltransferase 1, a protein used in the mitochondria to convert saturated fatty acids  
446 into glycerolipids. *GPAM* is highly expressed in liver<sup>48,49</sup> and associated with metabolic disease<sup>50</sup>,  
447 consistent with our pleiotropy analyses. Mouse knockouts of *GPAM* had reduced weight, lower  
448 hepatic triacylglycerol content, and decreased plasma triacylglycerol<sup>51</sup>. Another example is *MTTP*  
449 which is tagged by the missense variant rs3816873 (Ile128Thr, EA  $r^2=1.0$ ) and encodes the  
450 microsomal triglyceride transfer protein, which loads lipids onto assembling VLDL particles and  
451 facilitate their secretion by hepatocytes. Liver-specific *MTTP* knockout mice have reduced VLDL  
452 secretion and increased hepatic steatosis<sup>52</sup>. Lomitapide, a small molecule inhibitor of *MTTP*, is  
453 approved as a treatment for lowering LDL cholesterol in homozygous familial  
454 hypercholesterolemia, but increases liver lipid by inhibiting VLDL secretion<sup>53</sup>. *TRIM5* (Val112Phe)  
455 is a member of the tripartite motif (TRIM) family with E3 ubiquitin ligase activity with a key role  
456 in innate immune signaling and antiviral host defense<sup>54</sup>, and *TRIM5* SNPs have been associated  
457 with increased risk of liver fibrosis in HIV/HCV co-infected patients<sup>55</sup>. *APOH* (Cys325Gly) encodes  
458 the apolipoprotein H which is exclusively expressed in liver tissue<sup>48</sup> and which is associated with

459 ALT, AST, triglycerides, LDL cholesterol and platelets in the MVP labWAS. Two coding variants  
460 (strongly linked) in MerTK (Arg466Lys and Ile518Val,  $r^2=0.98$ ) were associated with NAFLD; MerTK  
461 signaling in hepatic macrophages was recently shown to mediate hepatic stellate cell activation  
462 and promote hepatic fibrosis progression<sup>56</sup>, and variants in *MERTK* were associated with liver  
463 fibrosis progression in HCV-infected patients<sup>57</sup>, raising the possibility for MerTK as a novel  
464 therapeutic target against fibrosis<sup>58</sup>. We emphasize that functional studies of our nominated  
465 causal genes are needed to demonstrate casual relevance, their impact on hepatosteatosis, and  
466 ultimately to determine their underlying mechanisms.

467         Given the complex etiology and progression of NAFLD, we anticipated that our study  
468 would identify novel loci with putatively causal genes that span multiple molecular pathways.  
469 Indeed, our novel loci include genes that play roles in obesity (e.g., *FTO*, *PPARG*), insulin  
470 resistance (e.g., *COBLL1*, *MIR5702 [IRS1]*), and diabetes (e.g., *HNF1A*). Relevant for hepatic  
471 inflammation in the two-hit hypothesis of NAFLD<sup>59</sup>, our novel loci also implicate immune-  
472 mediated or inflammatory contributions to NAFLD progression, including *HLA*, *RORA*<sup>60,61</sup>,  
473 *IFI30*<sup>62,63</sup>, *CD276*<sup>64</sup>, *ILRN*<sup>62,65</sup>, *ITCH*<sup>66,67</sup> and *P2RX7*<sup>68-70</sup>. Among these, *RORA* encodes the retinoic  
474 acid receptor related orphan receptor A which may be involved in NASH pathogenesis through  
475 macrophage polarization and miRNA122, which comprises 70% of the total miRNA in liver<sup>60,61</sup>. It  
476 is also known that loss of *TRIB1* substantially decreases miR-122 levels via its impact on *HNF4* and  
477 *HNF1A*<sup>71</sup>. *IFI30* encodes gamma-interferon-inducible lysosomal thiol reductase (GILT) which is  
478 involved in antigen processing and presentation and the production of reactive oxygen species  
479 during cellular stress and autophagy. Finally, *P2RX7* encodes the purinergic receptor P2X7 which  
480 is involved in inflammasome activation and IL-1 $\beta$  processing in liver inflammation and fibrosis<sup>68-</sup>

481 <sup>70</sup>. Encouragingly, these and additional pathways have emerged despite the proxy nature of our  
482 phenotype, and almost certainly underestimate the true number of loci contributing to NAFLD.

483 In conclusion, we define 77 trans-ancestry loci (70 novel) with 3 additional ancestry-  
484 specific loci associated with NAFLD by using chronic ALT elevation in a large, ancestrally diverse  
485 cohort enriched for metabolic disorders without other known causes of liver disease. The  
486 abundance of NAFLD loci identified by our analyses constitutes a much-needed large-scale, multi-  
487 ancestry genetic resource that can be used to build prediction models, identify causal  
488 mechanisms, and understand biological pathways contributing to NAFLD initiation and disease  
489 progression.

490

## 491 **Methods**

492

493 We performed a large-scale trans-ancestry NAFLD GWAS in the Million Veteran Program. We  
494 subsequently conducted analyses to facilitate the prioritization of these individual findings,  
495 including transcriptome-wide predicted gene expression for NAFLD, secondary signal analysis,  
496 coding variant mapping, phenome-wide association analyses in various public data sources, and  
497 various forms of cardiometabolic cross-trait colocalization analyses to fine-map the genomic loci  
498 to putatively causal genes.

499

### 500 *Discovery cohort.*

501 The Million Veteran Program (MVP) is a large cohort of fully consented veterans of the United  
502 States military forces recruited from 63 participating Department of Veterans Affairs (VA) medical  
503 facilities<sup>28</sup>. Recruitment for this ongoing sample started in 2011, and all veterans are eligible to

504 participate. This study analyzed clinical data through July 2017 for participants who were enrolled  
505 since January 2011. All MVP study participants provided blood samples for DNA extraction and  
506 genotyping, completed surveys about their health, lifestyle, and military experiences. Consent to  
507 participate and permission to re-contact was provided after veterans received information  
508 materials by mail and met with research staff to address their questions. Study participation also  
509 includes access to the participant's electronic health records for research purposes. Each  
510 veteran's electronic health care record is integrated into the MVP biorepository, including  
511 inpatient International Classification of Diseases (ICD-9-CM and ICD-10-CM) diagnosis codes,  
512 Current Procedural Terminology (CPT) procedure codes, clinical laboratory measurements, and  
513 reports of diagnostic imaging modalities. Researchers are provided with de-identified data, and  
514 have neither the ability nor authorization to link these details with a participant's identity. Blood  
515 samples are collected by phlebotomists and banked at the VA Central Biorepository in Boston,  
516 where DNA is extracted and shipped to two external centers for genotyping. The MVP received  
517 ethical and study protocol approval from the VA Central Institutional Review Board (IRB) in  
518 accordance with the principles outlined in the Declaration of Helsinki.

519 Genotyping: DNA extracted from buffy coat was genotyped using a custom Affymetrix Axiom  
520 biobank array. The MVP 1.0 genotyping array contains a total of 723,305 SNPs, enriched for 1)  
521 low frequency variants in AA and HISP populations, and 2) variants associated with diseases  
522 common to the VA population <sup>28</sup>.

523 Genotype quality-control: The MVP genomics working group applied standard quality control and  
524 genotype calling algorithms to the data in three batches using the Affymetrix Power Tools Suite  
525 (v1.18). Excluded were duplicate samples, samples with more heterozygosity than expected, and



526 samples with an over 2.5% missing genotype calls. We excluded related individuals (halfway  
527 between second- and third-degree relatives or closer) with KING software<sup>72</sup>. Before imputation,  
528 variants that were poorly called or that deviated from their expected allele frequency based on  
529 reference data from the 1000 Genomes Project were excluded<sup>73</sup>. After prephasing using EAGLE  
530 v2, genotypes were imputed via Minimac4 software<sup>74</sup> from the 1000 Genomes Project phase 3,  
531 version 5 reference panel. The top 30 principal components (PCs) were computed using FlashPCA  
532 in all MVP participants and an additional 2,504 individuals from 1000 Genomes. These PCs were  
533 used to unify of self-reported race/ancestry and genetically inferred ancestry to compose  
534 ancestral groups<sup>29</sup>.

535 Phenotype classification: MVP NAFLD phenotype definitions were developed by combining a  
536 previously published VA CDW ALT-based approach with non-invasive clinical parameters  
537 available to practicing clinicians at the point of care. The primary NAFLD phenotype (labeled  
538 “ALT-threshold”) was defined by: (i) elevated ALT >40 U/L for men and >30 U/L for women during  
539 at least two time points at least 6 months apart within a two-year window period at any point  
540 prior to enrollment and (ii) exclusion of other causes of liver disease (e.g. presence of chronic  
541 viral hepatitis B or C [defined as positive hepatitis C RNA > 0 international units/mL or positive  
542 hepatitis B surface antigen], chronic liver diseases or systemic conditions [e.g. hemochromatosis,  
543 primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, alpha-1-  
544 antitrypsin deficiency, sarcoidosis, metastatic liver cancer, secondary biliary cirrhosis, Wilson’s  
545 disease], and/or alcohol use disorder [e.g. alcohol use disorder, alcoholic liver disease, alcoholic  
546 hepatitis and/or ascites, alcoholic fibrosis and sclerosis of liver, alcoholic cirrhosis of liver and/or  
547 ascites, alcoholic hepatic failure and/or coma, and unspecified alcoholic liver disease). The

548 control group was defined by having a: normal ALT ( $\leq 30$  U/L for men,  $\leq 20$  U/L for women) and  
549 no apparent causes of liver disease or alcohol use disorder or related conditions<sup>21</sup>. Habitual  
550 alcohol consumption was assessed with the age-adjusted Alcohol Use Disorders Identification  
551 Test (AUDIT-C) score, a validated questionnaire annually administered by VA primary care  
552 practitioners and used previously in MVP<sup>75,76</sup>.

553

#### 554 *Single-variant autosomal analyses.*

555 We tested imputed SNPs that passed quality control (i.e. HWE  $> 1 \times 10^{-10}$ , INFO  $> 0.3$ , call rate  $>$   
556  $0.975$ ) for association with NAFLD through logistic regression assuming an additive model of  
557 variants with MAF  $> 0.1\%$  in European American (EA), and MAF  $> 1\%$  in African Americans (AA),  
558 Hispanics (HISP), and Asians (ASN) using PLINK2a software<sup>77</sup>. Covariates included age, gender,  
559 age-adjusted AUDIT-C score, and 10 principal components of genetic ancestry. We aggregated  
560 association summary statistics from the ancestry-specific analyses and performed a trans-  
561 ancestry meta-analysis. The association summary statistics for each analysis were meta-analyzed  
562 in a fixed-effects model using METAL with inverse-variance weighting of log odds ratios<sup>78</sup>.  
563 Variants were clumped using a range of 500kb and/or CEU  $r^2$  LD  $> 0.05$ , and were considered  
564 genome-wide significant if they passed the conventional p-value threshold of  $5.0 \times 10^{-8}$ .

565

#### 566 *Secondary signal analysis.*

567 GCTA<sup>79</sup> was used to conduct conditional analyses to detect ancestry-specific distinct association  
568 signals at each of the lead SNPs utilizing the GWAS summary statistics in EA, AA, and HISP; these  
569 ancestry-stratified MVP cohorts were used to model LD patterns between variants. The reference

570 panel of genotypes consisted of the variants with allele frequencies > 0.1% in EA, >1% in AA, and  
571 >1% in HISP that passed quality control criteria in the MVP-specific NAFLD GWAS (INFO > 0.3,  
572 HWE  $P > 1.0 \times 10^{-10}$ , call rate > 0.975). For each lead SNP, conditionally independent variants that  
573 reached locus-wide significance ( $P < 1.0 \times 10^{-5}$ ) were considered secondary signals of distinct  
574 association. If the minimum distance between any distinct signals from two separate loci was less  
575 than 500kb, we performed an additional conditional analysis that included both regions and  
576 reassessed the independence of each signal.

577

#### 578 *Credible Sets.*

579 We calculated Wakefield's approximate Bayes' factors<sup>30</sup> based on the marginal summary  
580 statistics of the trans-ancestry meta-analysis and ancestry specific summary statistics using the  
581 CRAN R package `corrcoverage`<sup>80</sup>. For each locus, the posterior probabilities of each variant being  
582 causal were calculated and a 95% credible set was generated which contains the minimum set of  
583 variants that jointly have at least 95% posterior probability (PP) of including the causal variant.

584

#### 585 *Concordance of NAFLD with qHF.*

586 For 77 lead trans-ancestry SNPs a concordance analysis was performed to evaluate the extent to  
587 which genetic predictors of hepatocellular injury (cALT) correspond with quantitative hepatic fat  
588 derived from computed tomography (CT) / magnetic resonance imaging (MRI)-measured hepatic  
589 fat in the Penn Medicine Biobank (PMBB), UK Biobank, Multi-Ethnic Study of Atherosclerosis  
590 (MESA), Framingham Heart Study (FHS), and University of Maryland Older Order Amish study.  
591 Attenuation was measured in Hounsfield units. The difference between the spleen and liver

592 attenuation was measured for PMBB; a ratio between liver attenuation/spleen attenuation was  
593 used for MESA and Amish; and liver attenuation/phantom attenuation ratio in FHS as previously  
594 described by Speliotes *et al*<sup>12</sup>. Abdominal MRI data from UK Biobank data were used to quantify  
595 liver fat using a two-stage machine learning approach with deep convolutional neural networks<sup>81</sup>.  
596 CT-measured hepatic fat was estimated using a multi-stage series of neural networks for  
597 presence of scan contrast and liver segmentation using convolutional neural networks. The PMBB  
598 included CT data on 2,979 EA and 1,250 AA participants<sup>82</sup>, the FHS included a total of 3,011 EA  
599 participants, the Amish study 754 EA participants, and MESA contributed 1,525 EA, 1,048 AA, 923  
600 HISP, and 360 ASN participants for concordance analysis. The UK Biobank included MRI image  
601 data from 36,703 EA participants. All cohorts underwent individual-level linear regression  
602 analysis on hepatic fat, adjusted for the covariates of age, gender, first 10 principal components  
603 of genetic ancestry, and alcohol intake if available. If the lead SNP was not available in any of the  
604 studies, a proxy SNP in high LD with the lead variant was used ( $r^2 > 0.7$ ) or if no such variant was  
605 identified, the SNP was set to missing for that respective study. The study-specific ancestry-  
606 stratified summary statistics were first standardized to generate standard scores or normal  
607 deviates (z-scores), and then meta-analyzed using METAL in a fixed-effects model with inverse-  
608 variance weighting of regression coefficients<sup>78</sup>. In a first round of meta-analysis, ancestry-specific  
609 summary statistics were generated, which then served as input for a subsequent round of meta-  
610 analysis that represents the trans-ancestry effects of our lead SNPs on quantitative hepatic fat.  
611  
612 *Heritability estimates and genetic correlations analysis.*

613 LD-score regression was used to estimate the heritability coefficient, and subsequently  
614 population and sample prevalence estimates were applied to estimate heritability on the liability  
615 scale<sup>83</sup>. A genome-wide genetic correlation analysis was performed to investigate possible co-  
616 regulation or a shared genetic basis between T2D and other complex traits and diseases. Pairwise  
617 genetic correlation coefficients were estimated between the meta-analyzed NAFLD GWAS  
618 summary output in EA and each of 774 precomputed and publicly available GWAS summary  
619 statistics for complex traits and diseases by using LD score regression through LD Hub v1.9.3  
620 (<http://ldsc.broadinstitute.org>). Statistical significance was set to a Bonferroni-corrected level of  
621  $P < 6.5 \times 10^{-5}$ .

622

### 623 *Tissue- and epigenetic-specific enrichment of NAFLD heritability.*

624 We analyzed cell type-specific annotations to identify enrichments of NAFLD heritability. First, a  
625 baseline gene model was generated consisting of 53 functional categories, including UCSC gene  
626 models, ENCODE functional annotations<sup>84</sup>, Roadmap epigenomic annotations<sup>85</sup>, and FANTOM5  
627 enhancers<sup>86</sup>. Gene expression and chromatin data were also analyzed to identify disease-relevant  
628 tissues, cell types, and tissue-specific epigenetic annotations. We used LDSC<sup>31-33</sup> to test for  
629 enriched heritability in regions surrounding genes with the highest tissue-specific expression.  
630 Sources of data that were analyzed included 53 human tissue or cell type RNA-seq data from  
631 GTEx<sup>27</sup>; human, mouse, or rat tissue or cell type array data from the Franke lab<sup>87</sup>; 3 sets of mouse  
632 brain cell type array data from Cahoy *et al*<sup>88</sup>; 292 mouse immune cell type array data from  
633 ImmGen<sup>89</sup>; and 396 human epigenetic annotations from the Roadmap Epigenomics Consortium  
634 <sup>85</sup>.

635

636 *Pathway Annotation enrichment.*

637 Enrichment analyses in DEPICT<sup>90</sup> were conducted using genome-wide significant ( $P < 5 \times 10^{-8}$ )

638 NAFLD GWAS lead SNPs. DEPICT is based on predefined phenotypic gene sets from multiple

639 databases and Affymetrix HGU133a2.0 expression microarray data from >37k subjects to build

640 highly-expressed gene sets for Medical Subject Heading (MeSH) tissue and cell type annotations.

641 Output includes a P-value for enrichment and a yes/no indicator of whether the FDR q-value is

642 significant ( $P < 0.05$ ). Tissue and gene-set enrichment features are considered. We tested for

643 epigenomic enrichment of genetic variants using GREGOR software<sup>91</sup>. We selected EA-specific

644 NAFLD lead variants with a p-value less than  $5 \times 10^{-8}$ . We tested for enrichment of the resulting

645 GWAS lead variants or their LD proxies ( $r^2$  threshold of 0.8 within 1 Mb of the GWAS lead, 1000

646 Genomes Phase I) in genomic features including ENCODE, Epigenome Roadmap, and manually

647 curated data (**Supplemental Table 24**). Enrichment was considered significant if the enrichment

648 p-value was less than the Bonferroni-corrected threshold of  $P=1.8 \times 10^{-5}$  ( $0.05/2,725$  tested

649 features).

650

651 *Coding variant mapping.*

652 All imputed variants in MVP were evaluated with Ensemble variant effect predictor<sup>92</sup>, and all

653 predicted LoF and missense variants were extracted. The LD was calculated with established

654 variants for trans-ancestry, EA, AA, and HISP lead SNPs based on 1000 Genomes reference

655 panel<sup>73</sup>. For SNPs with low allele frequencies, the MVP dataset was used for LD calculation for

656 the respective underlying population. For the trans-ancestry coding variant, the EA panel was

657 used for LD calculation. Coding variants that were in strong LD ( $r^2 > 0.7$ ) with lead SNPs and had  
658 a strong statistical association ( $P\text{-value} < 1 \times 10^{-5}$ ) were considered the putative causal drivers of  
659 the observed association at the respective locus.

660

#### 661 *Colocalization with gene expression*

662 GWAS summary statistics were lifted over from GRCh37 to GRCh38 using LiftOver  
663 (<https://genome.ucsc.edu/cgi-bin/hgLiftOver>). Colocalization analysis was run separately for  
664 each of the 49 tissues in GTEx v8<sup>27</sup>. For each tissue, we obtained an LD block for the genome with  
665 a sentinel SNP at  $P < 5 \times 10^{-8}$ , and then restricted analysis to the LD blocks. For each LD block with  
666 a sentinel SNP, all genes within 1Mb of the sentinel SNP (cis-Genes) were identified, and then  
667 restricted to those that were identified as eGenes in GTEx v8 at an FDR threshold of 0.05 (cis-  
668 eGenes). For each cis-eGene, we performed colocalization using all variants within 1Mb of the  
669 gene using the default prior probabilities in the 'coloc' function for the coloc package in R. We  
670 first assessed each coloc result for whether there was sufficient power to test for colocalization  
671 ( $PP3+PP4 > 0.8$ ), and for the colocalization pairs that pass the power threshold, we defined the  
672 significant colocalization threshold as  $PP4/(PP3+PP4) > 0.9$ .

673

#### 674 *Overlap with open chromatin.*

675 At each of the 77 NAFLD-associated loci from the trans-ancestry meta-analysis, we looked for  
676 overlaps between any variant in the credible set, and regions of open chromatin previously  
677 identified using ATAC-Seq experiments in two cell types—3 biological replicates of HepG2<sup>93</sup> and  
678 3 biological replicates of hepatocyte-like cells (HLC)<sup>94</sup> produced by differentiating three biological

679 replicates of iPSCs, which in turn were generated from peripheral blood mononuclear cells using  
680 a previously published protocol<sup>36</sup>.

681

682 *Overlap with Promoter Capture-C data.*

683 We used two promoter Capture-C datasets from two cell/tissue types to capture physical  
684 interactions between gene promoters and their regulatory elements and genes; three biological  
685 replicates of HepG2 liver carcinoma cells, and hepatocyte-like cells (HLC)<sup>93</sup>. The detailed protocol  
686 to prepare HepG2 or HLC cells for the promoter Capture-C experiment is previously described<sup>36</sup>.

687 Briefly, for each dataset, 10 million cells were used for promoter Capture-C library generation.

688 Custom capture baits were designed using an Agilent SureSelect library design targeting both

689 ends of DpnII restriction fragments encompassing promoters (including alternative promoters)

690 of all human coding genes, noncoding RNA, antisense RNA, snRNA, miRNA, snoRNA, and lincRNA

691 transcripts, totaling 36,691 RNA baited fragments. Each library was then sequenced on an

692 Illumina NovoSeq (HLC), or Illumina HiSeq 4000 (HLC), generating 1.6 billion read pairs per sample

693 (50 base pair read length.) HiCUP<sup>95</sup> was used to process the raw FastQ files into loop calls; we

694 then used CHICAGO<sup>96</sup> to define significant looping interactions; a default score of 5 was defined

695 as significant. We identified those NAFLD loci at which at least one variant in the credible set

696 interacted with an annotated bait in the Capture-C data.

697

698 *Protein-Protein Interaction Network Analysis*

699 We employed the search tool for retrieval of interacting genes (STRING) v11<sup>97</sup> (<https://string->

700 [db.org](https://string-db.org)) to seek potential interactions between nominated genes. STRING integrates both known



701 and predicted PPIs and can be applied to predict functional interactions of proteins. In our study,  
702 the sources for interaction were restricted to the ‘Homo Sapiens’ species and limited to  
703 experimentally validated and curated databases. An interaction score  $> 0.4$  were applied to  
704 construct the PPI networks, in which the nodes correspond to the proteins and the edges  
705 represent the interactions (**Figure 4, Supplemental Table 32**).

706

#### 707 *Gene Nomination.*

708 Based on DEPICT gene prediction, coding variant linkage analysis, QTL analysis, and annotation  
709 enrichment, and PPI networks (**Supplemental Tables 24-33**), a total of 215 potentially relevant  
710 genes for NAFLD were mapped to trans-ancestry 77 loci. For each locus with multiple mapped  
711 genes, we counted how many times each gene was identified through each of the analysis, and  
712 divided this by the total number of experiments (i.e., 8) to calculate an evidence burden that  
713 ranges from 0 to 100%. For each genomic locus, the gene that was most frequently identified as  
714 potentially relevant was selected as the putative causal gene. In the case of a tie break, and if  
715 the respective genes have identical nomination profiles, the gene with more eQTLs was  
716 selected as the putative causal gene. Similarly, gene nomination was preferred for loci that  
717 strongly tagged ( $r^2 > 0.8$ ) a coding variant. Loci that scored with 3 pieces of evidence or greater  
718 are listed for coding variant (**Table 1A**) and non-coding variants (**Table 1B**), respectively.

719

#### 720 *MVP LabWAS.*

721 A total of 21 continuous traits in the discovery MVP dataset, e.g. AST, ALP, fasting TG, HDL, LDL,  
722 TC, random glucose, HbA1c, albumin, bilirubin, platelet count, BMI, blood urea nitrogen (BUN),

723 creatinine, eGFR, SBP, DBP, ESR, INR, and C-reactive protein were tested in 186,681 EA's with  
724 association of 77 SNPs using linear regression of log-linear values. Covariates included age,  
725 gender and first 10 principal components of EA ancestry.

726

727 *PheWAS with UK Biobank data.*

728 For the 77 lead trans-ancestry SNPs and EA and AA specific SNPs, we performed a PheWAS in a  
729 genome-wide association study of EHR-derived ICD billing codes from the White British  
730 participants of the UK Biobank using PheWeb<sup>98</sup>. In short, phenotypes were classified into 1,403  
731 PheWAS codes excluding SNP-PheWAS code association pairs with case counts less than fifty<sup>99</sup>.  
732 All individuals were imputed using the Haplotype Reference Consortium panel <sup>100</sup>, resulting in  
733 the availability of 28 million genetic variants for a total of 408,961 subjects. Analyses on binary  
734 outcomes were conducted using a model named SAIGE, adjusted for genetic relatedness, gender,  
735 year of birth and the first 4 principal components of white British genetic ancestry<sup>101</sup>. SAIGE  
736 stands for Scalable and Accurate Implementation of GEneralized mixed model and represents a  
737 generalized mixed-model association test that accounts for case-control imbalance and sample  
738 relatedness<sup>101</sup>.

739

740 *IEU OpenGWAS project SNP lookup.*

741 An additional phenome-wide lookup was performed for 77 lead trans-ancestry SNPs and EA and  
742 AA specific SNPs in Bristol University's MRC Integrative Epidemiology Unit (IEU) GWAS  
743 database<sup>102</sup>. This database consists of 126,114,500,026 genetic associations from 34,494 GWAS  
744 summary datasets, including UK Biobank (<http://www.nealelab.is/uk-biobank>), FinnGen

745 (<https://github.com/FINNGEN/pheweb>), Biobank Japan (<http://jenger.riken.jp/result>), NHGRI-  
746 EBI GWAS catalog (<https://www.ebi.ac.uk/gwas>), blood metabolites GWAS<sup>103</sup>, circulating  
747 metabolites GWAS<sup>104</sup>, the MR-Base manually curated database<sup>105</sup>, and protein level GWAS<sup>106</sup>.

748

749 *Regional cardiometabolic cross-trait colocalization.*

750 Bayesian colocalization tests between NAFLD-associated signals and the following trait- and  
751 disease-associated signals were performed using the COLOC R package<sup>107</sup>. To enable cross-trait  
752 associations, we compiled summary statistics of 36 cardiometabolic and blood cell-related  
753 quantitative traits and disease from GWAS studies conducted in EA ancestry individuals, and for  
754 MVP-based reports also on AA and HISP. To summarize, for total, HDL, and LDL cholesterol,  
755 triglycerides, alcohol use disorder, alcohol intake, systolic blood pressure, diastolic blood  
756 pressure, type 2 diabetes, BMI, CAD, we used the summary statistics available from various MVP-  
757 based studies<sup>26,75,108</sup>. Of these, the summary statistics for CAD and BMI GWAS have not been  
758 published or deposited as of yet. Data on WHR were derived from GIANT Consortium<sup>109</sup>, whereas  
759 summary statistics on CKD, gout, blood urea nitrogen, urate, urinary albumin-to-creatinine ratio,  
760 microalbuminuria, and eGFR were derived from CKD Genetics Consortium<sup>110-112</sup>. Finally,  
761 summary statistics of blood cell traits (e.g. platelet count, albumin, white blood cells, basophils,  
762 eosinophils, neutrophils, hemoglobin, hematocrit, immature reticulocyte fraction, lymphocytes,  
763 monocytes, reticulocytes, mean corpuscular hemoglobin, mean corpuscular volume, mean  
764 platelet volume, platelet distribution width, and red cell distribution width) were derived from a  
765 large-scale GWAS report performed in UK Biobank and INTERVAL studies<sup>113</sup>. A colocalization test  
766 was performed for all 77 NAFLD loci spanning 500kb region around the lead SNP for all 36

767 compiled traits. COLOC requires for each SNP data on allele frequency, sample size, beta-  
768 coefficients and variance or p values. For each association pair COLOC was run with default  
769 parameters and priors. COLOC computed posterior probabilities for the following five  
770 hypotheses: PP0, no association with trait 1 (NAFLD GWAS signal) or trait 2 (e.g., co-associated  
771 metabolic signal); PP1, association with trait 1 only (i.e., no association with trait 2); PP2,  
772 association with trait 2 only (i.e., no association with trait 1); PP3, association with trait 1 and  
773 trait 2 by two independent signals; and PP4, association with trait 1 and trait 2 by shared variants.  
774 Evidence of colocalization<sup>114</sup> was defined by  $PP3 + PP4 \geq 0.99$  and  $PP4/PP3 \geq 5$ .

775

776 *NAFLD Polygenic risk score and NAFLD risk.*

777 We constructed polygenic risk score (PRS) for NAFLD in the Stage 2 replication data set containing  
778 of 73,580 MVP participants of EA ancestry by calculating a linear combination of weights derived  
779 from the discovery MVP dataset of lead 77 trans-ancestry variants. The PRS was divided into  
780 quintiles and the risk of NAFLD was assessed using a logistic regression model using the lowest  
781 decile as a reference (e.g. the 20% of participants with lowest of NAFLD PRS), together with the  
782 potential confounding factors of age, gender, age-adjusted AUDIT-C, and the first 10 principal  
783 components of EA ancestry.

784

785 *NAFLD PRS Phewas*

786 For the NAFLD PRS that was generated using the Stage 1 350K dataset, we performed a PheWAS  
787 study in the Stage 2 108K replication dataset to fully leverage full catalog of available ICD-9/ICD-  
788 10 diagnosis codes. Of genotyped veterans, participants were included in the PheWAS analysis if

789 their respective electronic health record reflected two or more separate encounters in the VA  
790 Healthcare System in MVP up to July 2017. Using this method, a total of 73,580 veterans of EA  
791 ancestry were available for PheWAS analysis. ICD-9/ICD-10 diagnosis codes were collapsed to  
792 clinical disease groups and corresponding controls using predefined groupings<sup>99</sup>. Phenotypes  
793 were required to have a case count over 25 in order to be included in the PheWAS analysis, and  
794 a multiple testing thresholds for statistical significance was set to  $P < 2.8 \times 10^{-5}$  (Bonferroni  
795 method). The NAFLD PRS was used as a continuous exposure variable in a logistic regression  
796 adjusting for age, sex, age-adjusted AUDIT-C, and 10 principal components in an additive effects  
797 model using the PheWAS R package in R v3.2.065. The results from these analyses are reported  
798 as odds ratios, in which the estimate is the average change in odds of the PheWAS trait per  
799 NAFLD-increasing polygenic risk score.

800

#### 801 *Transcription Factor Analysis.*

802 We identified nominated genes (**Supplemental Table 34**) that encode for TFs based on known  
803 motifs, inferred motifs from similar proteins, and likely sequence specific TFs according to  
804 literature or domain structure<sup>115</sup>. Target genes for these TFs were extracted using DoRothEA  
805 database<sup>116</sup> in OmniPath collection<sup>117</sup> using the associated Bioconductor R package  
806 OmnipathR<sup>118</sup>, a gene set resource containing TF-TF target interactions curated from public  
807 literature resources, such as CHIP-seq peaks, TF binding site motifs and interactions inferred  
808 directly from gene expression.

809

810

## 811 **Acknowledgements**

812 This research is based on data from the Million Veteran Program, Office of Research and  
813 Development, Veterans Health Administration and was supported by award no. MVP000. This  
814 publication does not represent the views of the Department of Veterans Affairs, the US Food and  
815 Drug Administration, or the US Government. This research was also supported by funding from:  
816 the Department of Veterans Affairs awards I01- BX003362 (P.S.T. and K.M.C) and I01BX003341  
817 (H.R.K. Co-Principal Investigator) and the VA Informatics and Computing Infrastructure (VINCI)  
818 VA HSR RES 130457 (S.L.D). B.F.V. acknowledges support for this work from the NIH/NIDDK  
819 (DK101478 and DK126194) and a Linda Pechenik Montague Investigator award. K.M.C, S.M.D,  
820 J.M.G, C.J.O, L.S.P, and P.S.T. are supported by the VA Cooperative Studies Program. S.M.D. is  
821 supported by the Veterans Administration [IK2 CX001780]. Funding support is also acknowledged  
822 for MS (K23 DK115897), R.M.C (R01 AA026302), D.K. (National Heart, Lung, and Blood Institute  
823 of the National Institutes of Health [T32 HL007734]), L.S.P. (VA awards I01 CX001025, and I01  
824 CX001737, NIH awards R21 DK099716, U01 DK091958, U01 DK098246, P30 DK111024, and R03  
825 AI133172, and a Cystic Fibrosis Foundation award PHILLI12A0). The Rader lab was supported by  
826 NIH grants HL134853 (NJH and DJR) and DK114291-01A1 (K.T.C, N.J.H, and D.J.R). We thank all  
827 study participants for their contribution. Support for imaging studies was provided by ITMAT (NIH  
828 NCATS UL1TR001878), the Penn Center for Precision Medicine Accelerator Fund and R01  
829 HL137501. Data for external replication and hepatic fat concordance were provided by  
830 investigators using United Kingdom BioBank, Multi-Ethnic Study of Atherosclerosis (MESA), Old  
831 Order Amish Study (Amish), Framingham Heart Study (FHS) and Penn Medicine Biobank (PMBB).  
832

833 **MESA/MESA SHARe Acknowledgements:** MESA and the MESA SHARe projects are conducted  
834 and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with  
835 MESA investigators. This research was supported by R01 HL071739 and MESA was supported by  
836 contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-  
837 95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006,  
838 N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-  
839 95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-  
840 001420. Also supported in part by the National Center for Advancing Translational Sciences, CTSI  
841 grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease  
842 Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes  
843 Endocrinology Research Center.

844

#### 845 **Ethics statement**

846 The Central Veterans Affairs Institutional Review Board (IRB) and site-specific Research and  
847 Development Committees approved the Million Veteran Program study. All other cohorts  
848 participating in this meta-analysis have ethical approval from their local institutions. All relevant  
849 ethical regulations were followed.

850

#### 851 **Data availability**

852 The full summary level association data from the trans-ancestry, European, African American,  
853 Hispanic, and Asian meta-analysis from this report will be available through dbGAP (Accession  
854 codes will be available before publication).

855

856 **Disclosures**

857 H.R.K. is a member of a Dicerna scientific advisory board; a member of the American Society of  
858 Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which during the past three  
859 years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna,  
860 Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka; and is named as an inventor on PCT  
861 patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed  
862 January 24, 2018.



863 **Legends**

864

865 **Table 1a. Gene nominations at loci with strongest evidence for coding variants.**

SNP	Position	Gene	AA-Change	SIFT/PP2*	e/sQTL**	Other †	Pleiotropy‡
rs6541349	1:93787867	CCDC18	p.Leu1134Val	+/-	+	.	M
rs2642438	1:220970028	MARC1	p.Thr165Ala	-/-	+(A)	+	M
rs11683409	2:112770134	MERTK	p.Arg466Lys	-/-	.	++	.
rs17036160	3:12329783	PPARG	p.Pro12Ala	-/-	+	++	M
rs17598226	4:100496891	MTTP	p.Ile128Thr	-/-	+	+	.
rs115038698	7:87024718	ABCB4	p.Ala934Thr	+/+	+	+	M,I
rs799165	7:73052057	MLXIPL	p.Gln241His	-/+	+	+	M,I
			p.Ala358Val	-/-	+	+	M,I
rs7041363	9:117146043	AKNA	p.Pro624Leu	+/-	+	+	M
rs10883451	10:101924418	ERLIN1	p.Ile291Val	-/-	.	++	M
rs4918722	10:113947040	GPAM	p.Ile43Val	-/-	+	++	M
rs11601507	11:5701074	TRIM5	p.Val112Phe	-/-	.	++	M,I
rs1626329	12:121622023	P2RX7	p.Ala348Thr	-/-	+	+	.
rs11621792	14:24871926	NYNRIN	p.Ala978Thr	-/-	+(L,A)	+	M,I
rs28929474	14:94844947	SERPINA1	p.Glu366Lys	-/+	.	+++	M,I
rs7168849	15:90346227	ANPEP	p.Ala311Val	-/-	+(L)	+	.
rs1801689	17:64210580	APOH	p.Cys325Gly	+/+	.	++	M,I
rs132665	22:36564170	APOL3	p.Ser39Arg	-/-	+(A)	+	.
rs738408	22:44324730	PNPLA3	p.Ile148Met	+/+	.	+++	M,I

866 Genes nominated with various sources of evidence are listed as follows.

867 \*Prio to the slash symbol: '+' indicates 'deleterious' in SIFT and '-' otherwise. After slash symbol: '+'  
 868 denotes probably damaging in Polyphen-2 and '-' otherwise.

869 \*\* The '+' indicates colocalization between NAFLD GWAS variant and GTEx QTL variant (COLOC  
 870 PP4/(PP3+PP4) > 0.9). (L) denotes QTL effect in Liver, (A) denotes QTL in Adipose.

871 †Each '+' represent evidence from DEPICT, PPI data, or if the lead SNP is within the transcript; coding  
 872 variants also include '+' from hQTLs/Capture-C evidence.

873 ‡Pleiotropy is limited to association with Metabolic (M) or Inflammatory (I) Traits

874

875

876 **Table 1b. Gene nominations at loci with strongest evidence for non-coding variants.**

SNP	Position	Gene	hQTL	CaptureC	e/sQTL**	Other †	Pleiotropy‡
rs36086195	1:16510894	EPHA2	.	+	+(L,A)	+	M
rs6734238	2:113841030	IL1RN	.	+	+(A)	++	I
rs10201587	2:202202791	CASP8	.	+	+	+	M
rs11683367	2:233510011	EFHD1	+	.	+(L)	+	.
rs61791108	3:170732742	SLC2A2	.	+	.	+++	M
rs7653249	3:136005792	PCCB	.	.	+	++	M,I
rs12500824	4:77416627	SHROOM3	.	+	+(L)	+	M
rs10433937	4:88230100	HSD17B13	.	.	+(L,A)	+	M,I
rs799165	7:73052057	BCL7B	.	+	+	+	M,I
rs687621	9:136137065	ABO	.	.	+	+	M,I
rs35199395	10:70983936	HKDC1	.	+	+(L,A)	+	M
rs174535	11:61551356	FADS2	+	.	+(A)	++	M,I
rs56175344	11:93864393	PANX1	.	.	+(L,A)	++	.
rs34123446	12:122511238	MLXIP	.	+	+	+	M,I
rs12149380	16:72043546	DHODH	.	+	+	+	M,I
		HP	.	+	+(A)	.	M,I
rs2727324	17:61922102	DDX42	.	+	+	+	M
		SMARCD2	.	.	+	+	M
rs5117	19:45418790	APOC1	.	.	+	++	M,I

877 Genes nominated with various sources of evidence are listed as follows.

878 \*Prio to the slash symbol: '+' indicates 'deleterious' in SIFT and '-' otherwise. After slash symbol: '+'  
879 denotes probably damaging in Polyphen-2 and '-' otherwise.

880 \*\* The '+' indicates colocalization between NAFLD GWAS variant and GTEx QTL varint (COLOC  
881 PP4/(PP3+PP4) > 0.9). (L) denotes QTL effect in Liver, (A) denotes QTL in Adipose.


882 †Each '+' represent evidence from DEPICT, PPI data, or if the lead SNP is within the transcript; coding  
883 variants also include '+' from hQTLs/Capture-C evidence.

884 ‡Pleiotropy is limited to association with Metabolic (M) or Inflammatory (I) Traits

885

886

887 **Figure 1. Overview of analysis pipeline.**



888

889 Left side of the flow diagram shows our study design with initial inclusion of 430,000 Million Veteran Program

890 participants with genotyping and ancestry classification by HARE, exclusion of individuals with known liver disease

891 or alcohol dependence and inclusion of subjects based on chronic ALT elevation (case) or normal ALT (control). This

892 resulted in 90,408 NAFLD cases and 128,187 controls with EA, AA, HISP and ASN ancestries that were examined in

893 primary trans-ancestry and ancestry-specific genome-wide association scans in discovery (stage 1) and internal

894 replication stages (stage 2) with further meta-analysis. Right side of the flow diagram highlights our results of trans-

895 ancestry and ancestry-specific meta-analyses identifying 77 trans-ancestry loci + 1 EA-specific + 2 AA-specific loci

896 that met genome-wide significance, with additional results of external replications, locus fine-mapping via GCTA,


897 signal fine-mapping (95% credible sets), heritability estimation and genetic correlations by LDSC, physiological

898 categorization of discovered loci based on pleiotropic trait associations (mainly liver, metabolic and inflammation),

899 candidate gene nomination and polygenic risk score.

900

901 **Figure 2. Manhattan plot of NAFLD GWAS of 90,408 NAFLD and 128, 187 controls in trans-**  
902 **ancestry meta-analysis.**




903  
904 Nominated genes are indicated for 77 loci reaching genome-wide significance ( $P < 5 \times 10^{-8}$ ).

905 Previously reported NAFLD-loci with genome-wide significant association are indicated in green  
906 font.


907  
908

909 **Figure 3. Chromosome 12 locus points to different genes in trans-ancestry (left) and European-**  
910 **only (right) analyses.**



911  
912 The lead variants in each analysis are highlighted. The orange arrow refers to the proxy SNP of  
913 rs1626329 in the European-only analysis.  
914

915 **Figure 4. Venn diagram depicting overlapping liver, metabolic and inflammatory traits among**  
 916 **NAFLD-associated loci.**



917  
 918 Overlapping liver (light blue), metabolic (pink) and/or inflammatory (green) traits are shown in  
 919 association with 77 trans-ancestry and additional ancestry-specific lead SNPs. The trait  
 920 categorizations reflect significant SNP-trait associations identified by: 1) LabWAS of clinical  
 921 laboratory results in MVP; 2) PheWAS with UKBB data using SAIGE; 3) SNP lookup using the  
 922 curated data in the IEU OpenGWAS projects; and 4) cross-trait colocalization analyses using  
 923 COLOC of EA, AA and HISP lead loci with 36 other GWAS statistics of cardiometabolic and blood  
 924 cell related traits. **Red/bold** font refers to the loci also associated with quantitative hepatic fat  
 925 on imaging analyses.

926

927

928 **References**

- 929 1. Asrani, S.K., Devarbhavi, H., Eaton, J. & Kamath, P.S. Burden of liver diseases in the  
930 world. *J Hepatol* **70**, 151-171 (2019).
- 931 2. Younossi, Z., Anstee, Q.M. & Marietti, M. Global burden of NAFLD and NASH: trends,  
932 predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* **15**(2018).
- 933 3. Carr, R.M., Oranu, A. & Khungar, V. Nonalcoholic Fatty Liver Disease: Pathophysiology  
934 and Management. *Gastroenterol Clin North Am* **45**, 639-652 (2016).
- 935 4. Chalasani, N. *et al.* The diagnosis and management of nonalcoholic fatty liver disease:  
936 Practice guidance from the American Association for the Study of Liver Diseases.  
937 *Hepatology* **67**, 328-357 (2018).
- 938 5. Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. & Sanyal, A.J. Mechanisms of  
939 NAFLD development and therapeutic strategies. *Nat Med* **24**, 908-922 (2018).
- 940 6. Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A.J. Modeling the epidemic of  
941 nonalcoholic fatty liver disease demonstrates an exponential increase in burden of  
942 disease. *Hepatology* **67**, 123-133 (2018).
- 943 7. Jarvis, H. *et al.* Metabolic risk factors and incident advanced liver disease in non-  
944 alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of  
945 population-based observational studies. *PLoS Med* **17**, e1003100 (2020).
- 946 8. Sookoian, S. & Pirola, C.J. Genetic predisposition in nonalcoholic fatty liver disease. *Clin*  
947 *Mol Hepatol* **23**, 1-12 (2017).
- 948 9. Romeo, S. *et al.* Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty  
949 liver disease. *Nat Genet* **40**, 1461-5 (2008).
- 950 10. Yuan, X. *et al.* Population-based genome-wide association studies reveal six loci  
951 influencing plasma levels of liver enzymes. *Am J Hum Genet* **83**, 520-8 (2008).
- 952 11. Chambers, J.C. *et al.* Genome-wide association study identifies loci influencing  
953 concentrations of liver enzymes in plasma. *Nat Genet* **43**, 1131-8 (2011).
- 954 12. Speliotes, E.K. *et al.* Genome-wide association analysis identifies variants associated  
955 with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLoS*  
956 *Genet* **7**, e1001324 (2011).
- 957 13. Feitosa, M.F. *et al.* The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat  
958 deposition and hepatic inflammation in the NHLBI Family Heart Study. *Atherosclerosis*  
959 **228**, 175-80 (2013).
- 960 14. Kozlitina, J. *et al.* Exome-wide association study identifies a TM6SF2 variant that confers  
961 susceptibility to nonalcoholic fatty liver disease. *Nat Genet* **46**, 352-6 (2014).
- 962 15. Liu, Y.L. *et al.* TM6SF2 rs58542926 influences hepatic fibrosis progression in patients  
963 with non-alcoholic fatty liver disease. *Nat Commun* **5**, 4309 (2014).
- 964 16. Abul-Husn, N.S. *et al.* A Protein-Truncating HSD17B13 Variant and Protection from  
965 Chronic Liver Disease. *N Engl J Med* **378**, 1096-1106 (2018).
- 966 17. Young, K.A. *et al.* Genome-Wide Association Study Identifies Loci for Liver Enzyme  
967 Concentrations in Mexican Americans: The GUARDIAN Consortium. *Obesity (Silver*  
968 *Spring)* **27**, 1331-1337 (2019).
- 969 18. Namjou, B. *et al.* GWAS and enrichment analyses of non-alcoholic fatty liver disease  
970 identify new trait-associated genes and pathways across eMERGE Network. *BMC Med*  
971 **17**, 135 (2019).

- 972 19. Emdin, C.A. *et al.* A missense variant in Mitochondrial Amidoxime Reducing Component  
973 1 gene and protection against liver disease. *PLoS Genet* **16**, e1008629 (2020).
- 974 20. Anstee, Q.M. *et al.* Genome-wide association study of non-alcoholic fatty liver and  
975 steatohepatitis in a histologically characterised cohort(). *J Hepatol* **73**, 505-515 (2020).
- 976 21. Serper, M. *et al.* Validating a Non-Invasive Non-Alcoholic Fatty Liver Phenotype in the  
977 Million Veteran Program. *PLoS One* (**in press**)(2020).
- 978 22. Chalasani, N. *et al.* Genome-wide association study identifies variants associated with  
979 histologic features of nonalcoholic Fatty liver disease. *Gastroenterology* **139**, 1567-76,  
980 1576 e1-6 (2010).
- 981 23. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity  
982 biology. *Nature* **518**, 197-206 (2015).
- 983 24. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body  
984 mass index in approximately 700000 individuals of European ancestry. *Hum Mol Genet*  
985 **27**, 3641-3649 (2018).
- 986 25. Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular  
987 outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet*  
988 **52**, 680-691 (2020).
- 989 26. Klarin, D. *et al.* Genetics of blood lipids among ~300,000 multi-ethnic participants of the  
990 Million Veteran Program. *Nat Genet* **50**, 1514-1523 (2018).
- 991 27. Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5  
992 (2013).
- 993 28. Gaziano, J.M. *et al.* Million Veteran Program: A mega-biobank to study genetic  
994 influences on health and disease. *J Clin Epidemiol* **70**, 214-23 (2016).
- 995 29. Fang, H. *et al.* Harmonizing genetic ancestry and self-identified race/ethnicity in  
996 genome-wide association studies. *Am J Hum Gen* **105**, 763-772 (2019).
- 997 30. Wakefield, J. Bayes factors for genome-wide association studies: comparison with P-  
998 values. *Genet Epidemiol* **33**, 79-86 (2009).
- 999 31. Finucane, H.K. *et al.* Partitioning heritability by functional annotation using genome-  
1000 wide association summary statistics. *Nat Genet* **47**, 1228-35 (2015).
- 1001 32. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from  
1002 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5 (2015).
- 1003 33. Finucane, H.K. *et al.* Heritability enrichment of specifically expressed genes identifies  
1004 disease-relevant tissues and cell types. *Nat Genet* **50**, 621-629 (2018).
- 1005 34. Adzhubei, I., Jordan, D.M. & Sunyaev, S.R. Predicting functional effect of human  
1006 missense mutations using PolyPhen-2. *Curr Protoc Hum Genet* **Chapter 7**, Unit7 20  
1007 (2013).
- 1008 35. Ng, P.C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function.  
1009 *Nucleic Acids Res* **31**, 3812-4 (2003).
- 1010 36. Caliskan, M. *et al.* Genetic and Epigenetic Fine Mapping of Complex Trait Associated Loci  
1011 in the Human Liver. *Am J Hum Genet* **105**, 89-107 (2019).
- 1012 37. Baxter, M. *et al.* Phenotypic and functional analyses show stem cell-derived hepatocyte-  
1013 like cells better mimic fetal rather than adult hepatocytes. *J Hepatol* **62**, 581-9 (2015).



- 1014 38. Goldstein, J.A. *et al.* LabWAS: novel findings and study design recommendations from a  
1015 meta-analysis of clinical labs in two independent biobanks. *medRxiv*,  
1016 2020.04.08.19011478 (2020).
- 1017 39. Replication, D.I.G. *et al.* Genome-wide trans-ancestry meta-analysis provides insight into  
1018 the genetic architecture of type 2 diabetes susceptibility. *Nat Genet* **46**, 234-44 (2014).
- 1019 40. Sticova, E. & Jirsa, M. ABCB4 disease: Many faces of one gene deficiency. *Ann Hepatol*  
1020 **19**, 126-133 (2020).
- 1021 41. Gudbjartsson, D.F. *et al.* Large-scale whole-genome sequencing of the Icelandic  
1022 population. *Nat Genet* **47**, 435-44 (2015).
- 1023 42. Stattermayer, A.F., Halilbasic, E., Wrba, F., Ferenci, P. & Trauner, M. Variants in ABCB4  
1024 (MDR3) across the spectrum of cholestatic liver diseases in adults. *J Hepatol* **73**, 651-663  
1025 (2020).
- 1026 43. Willebrords, J. *et al.* Protective effect of genetic deletion of pannexin1 in experimental  
1027 mouse models of acute and chronic liver disease. *Biochim Biophys Acta Mol Basis Dis*  
1028 **1864**, 819-830 (2018).
- 1029 44. Cooreman, A. *et al.* Connexin and Pannexin (Hemi)Channels: Emerging Targets in the  
1030 Treatment of Liver Disease. *Hepatology* **69**, 1317-1323 (2019).
- 1031 45. Mehta, M.B. *et al.* Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b)  
1032 promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis.  
1033 *J Biol Chem* **292**, 10444-10454 (2017).
- 1034 46. Stender, S. *et al.* Relationship between genetic variation at PPP1R3B and levels of liver  
1035 glycogen and triglyceride. *Hepatology* **67**, 2182-2195 (2018).
- 1036 47. Dwyer, A. *et al.* Influence of glycogen on liver density: computed tomography from a  
1037 metabolic perspective. *J Comput Assist Tomogr* **7**, 70-3 (1983).
- 1038 48. Fagerberg, L. *et al.* Analysis of the human tissue-specific expression by genome-wide  
1039 integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics* **13**,  
1040 397-406 (2014).
- 1041 49. Duff, M.O. *et al.* Genome-wide identification of zero nucleotide recursive splicing in  
1042 *Drosophila*. *Nature* **521**, 376-9 (2015).
- 1043 50. de Vries, P.S. *et al.* Multiancestry Genome-Wide Association Study of Lipid Levels  
1044 Incorporating Gene-Alcohol Interactions. *Am J Epidemiol* **188**, 1033-1054 (2019).
- 1045 51. Hammond, L.E. *et al.* Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice  
1046 have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid  
1047 composition. *Mol Cell Biol* **22**, 8204-14 (2002).
- 1048 52. Raabe, M. *et al.* Analysis of the role of microsomal triglyceride transfer protein in the  
1049 liver of tissue-specific knockout mice. *J Clin Invest* **103**, 1287-98 (1999).
- 1050 53. Cuchel, M. *et al.* Inhibition of microsomal triglyceride transfer protein in familial  
1051 hypercholesterolemia. *N Engl J Med* **356**, 148-56 (2007).
- 1052 54. van Gent, M., Sparrer, K.M.J. & Gack, M.U. TRIM Proteins and Their Roles in Antiviral  
1053 Host Defenses. *Annu Rev Virol* **5**, 385-405 (2018).
- 1054 55. Medrano, L.M. *et al.* Relationship of TRIM5 and TRIM22 polymorphisms with liver  
1055 disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. *J*  
1056 *Transl Med* **14**, 257 (2016).

- 1057 56. Cai, B. *et al.* Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis.  
1058 *Cell Metab* **31**, 406-421 e7 (2020).
- 1059 57. Patin, E. *et al.* Genome-wide association study identifies variants associated with  
1060 progression of liver fibrosis from HCV infection. *Gastroenterology* **143**, 1244-1252 e12  
1061 (2012).
- 1062 58. Wen, Y. & Ju, C. MerTK - A Novel Potential Target to Treat NASH Fibrosis. *Hepatology*  
1063 (2020).
- 1064 59. Day, C.P. From fat to inflammation. *Gastroenterology* **130**, 207-10 (2006).
- 1065 60. Han, Y.H. *et al.* A maresin 1/RORalpha/12-lipoxygenase autoregulatory circuit prevents  
1066 inflammation and progression of nonalcoholic steatohepatitis. *J Clin Invest* **129**, 1684-  
1067 1698 (2019).
- 1068 61. Chai, C. *et al.* Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice  
1069 via Up-regulation of MicroRNA 122. *Gastroenterology* **159**, 999-1014 e9 (2020).
- 1070 62. West, L.C. & Cresswell, P. Expanding roles for GILT in immunity. *Curr Opin Immunol* **25**,  
1071 103-8 (2013).
- 1072 63. Chiang, H.S. & Maric, M. Lysosomal thiol reductase negatively regulates autophagy by  
1073 altering glutathione synthesis and oxidation. *Free Radic Biol Med* **51**, 688-99 (2011).
- 1074 64. Chapoval, A.I. *et al.* B7-H3: a costimulatory molecule for T cell activation and IFN-gamma  
1075 production. *Nat Immunol* **2**, 269-74 (2001).
- 1076 65. Mirea, A.M., Tack, C.J., Chavakis, T., Joosten, L.A.B. & Toonen, E.J.M. IL-1 Family  
1077 Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies. *Trends Mol*  
1078 *Med* **24**, 458-471 (2018).
- 1079 66. Mueller, D.L. E3 ubiquitin ligases as T cell anergy factors. *Nat Immunol* **5**, 883-90 (2004).
- 1080 67. Kleine-Eggebrecht, N. *et al.* Mutation in ITCH Gene Can Cause Syndromic Multisystem  
1081 Autoimmune Disease With Acute Liver Failure. *Pediatrics* **143**(2019).
- 1082 68. Baeza-Raja, B. *et al.* Pharmacological inhibition of P2RX7 ameliorates liver injury by  
1083 reducing inflammation and fibrosis. *PLoS One* **15**, e0234038 (2020).
- 1084 69. Di Virgilio, F., Dal Ben, D., Sarti, A.C., Giuliani, A.L. & Falzoni, S. The P2X7 Receptor in  
1085 Infection and Inflammation. *Immunity* **47**, 15-31 (2017).
- 1086 70. Giuliani, A.L., Sarti, A.C., Falzoni, S. & Di Virgilio, F. The P2X7 Receptor-Interleukin-1  
1087 Liaison. *Front Pharmacol* **8**, 123 (2017).
- 1088 71. Soubeyrand, S., Martinuk, A., Naing, T., Lau, P. & McPherson, R. Role of Tribbles  
1089 Pseudokinase 1 (TRIB1) in human hepatocyte metabolism. *Biochim Biophys Acta* **1862**,  
1090 223-32 (2016).
- 1091 72. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.  
1092 *Bioinformatics* **26**, 2867-73 (2010).
- 1093 73. Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**,  
1094 68-74 (2015).
- 1095 74. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**,  
1096 1284-1287 (2016).
- 1097 75. Kranzler, H.R. *et al.* Genome-wide association study of alcohol consumption and use  
1098 disorder in 274,424 individuals from multiple populations. *Nat Commun* **10**, 1499  
1099 (2019).

- 1100 76. Justice, A.C. *et al.* AUDIT-C and ICD codes as phenotypes for harmful alcohol use:  
1101 association with ADH1B polymorphisms in two US populations. *Addiction* **113**, 2214-  
1102 2224 (2018).
- 1103 77. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer  
1104 datasets. *Gigascience* **4**, 7 (2015).
- 1105 78. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of  
1106 genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
- 1107 79. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide  
1108 complex trait analysis. *Am J Hum Genet* **88**, 76-82 (2011).
- 1109 80. Hutchinson, A., Watson, H. & Wallace, C. Correcting the coverage of credible sets in  
1110 Bayesian genetic fine-mapping. *bioRxiv*, 781062 (2019).
- 1111 81. Haas, M.E. *et al.* Machine learning enables new insights into clinical significance of and  
1112 genetic contributions to liver fat accumulation. *medRxiv*, 2020.09.03.20187195 (2020).
- 1113 82. MacLean, M.T. *et al.* Linking abdominal imaging traits to electronic health record  
1114 phenotypes. *medRxiv*, 2020.09.08.20190330 (2020).
- 1115 83. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.  
1116 *Nat Genet* **47**, 1236-41 (2015).
- 1117 84. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome.  
1118 *Nature* **489**, 57-74 (2012).
- 1119 85. Roadmap Epigenomics, C. *et al.* Integrative analysis of 111 reference human  
1120 epigenomes. *Nature* **518**, 317-30 (2015).
- 1121 86. Andersson, R. *et al.* An atlas of active enhancers across human cell types and tissues.  
1122 *Nature* **507**, 455-461 (2014).
- 1123 87. Fehrmann, R.S. *et al.* Gene expression analysis identifies global gene dosage sensitivity  
1124 in cancer. *Nat Genet* **47**, 115-25 (2015).
- 1125 88. Cahoy, J.D. *et al.* A transcriptome database for astrocytes, neurons, and  
1126 oligodendrocytes: a new resource for understanding brain development and function. *J*  
1127 *Neurosci* **28**, 264-78 (2008).
- 1128 89. Heng, T.S., Painter, M.W. & Immunological Genome Project, C. The Immunological  
1129 Genome Project: networks of gene expression in immune cells. *Nat Immunol* **9**, 1091-4  
1130 (2008).
- 1131 90. Pers, T.H. *et al.* Biological interpretation of genome-wide association studies using  
1132 predicted gene functions. *Nat Commun* **6**, 5890 (2015).
- 1133 91. Schmidt, E.M. *et al.* GREGOR: evaluating global enrichment of trait-associated variants in  
1134 epigenomic features using a systematic, data-driven approach. *Bioinformatics* **31**, 2601-  
1135 6 (2015).
- 1136 92. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).
- 1137 93. Chesi, A. *et al.* Genome-scale Capture C promoter interactions implicate effector genes  
1138 at GWAS loci for bone mineral density. *Nat Commun* **10**, 1260 (2019).
- 1139 94. Pashos, E.E. *et al.* Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-  
1140 like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. *Cell Stem*  
1141 *Cell* **20**, 558-570 e10 (2017).
- 1142 95. Wingett, S. *et al.* HiCUP: pipeline for mapping and processing Hi-C data. *F1000Res* **4**,  
1143 1310 (2015).

- 1144 96. Cairns, J. *et al.* CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C  
1145 data. *Genome Biol* **17**, 127 (2016).
- 1146 97. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased  
1147 coverage, supporting functional discovery in genome-wide experimental datasets.  
1148 *Nucleic Acids Res* **47**, D607-D613 (2019).
- 1149 98. Gagliano Taliun, S.A. *et al.* Exploring and visualizing large-scale genetic associations by  
1150 using PheWeb. *Nat Genet* **52**, 550-552 (2020).
- 1151 99. Denny, J.C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to  
1152 discover gene-disease associations. *Bioinformatics* **26**, 1205-10 (2010).
- 1153 100. Loh, P.R. *et al.* Reference-based phasing using the Haplotype Reference Consortium  
1154 panel. *Nat Genet* **48**, 1443-1448 (2016).
- 1155 101. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness  
1156 in large-scale genetic association studies. *Nat Genet* **50**, 1335-1341 (2018).
- 1157 102. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *bioRxiv*,  
1158 2020.08.10.244293 (2020).
- 1159 103. Shin, S.Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat Genet*  
1160 **46**, 543-550 (2014).
- 1161 104. Kettunen, J. *et al.* Genome-wide study for circulating metabolites identifies 62 loci and  
1162 reveals novel systemic effects of LPA. *Nat Commun* **7**, 11122 (2016).
- 1163 105. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the  
1164 human phenome. *Elife* **7**(2018).
- 1165 106. Sun, B.B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73-79 (2018).
- 1166 107. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic  
1167 association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
- 1168 108. Giri, A. *et al.* Trans-ethnic association study of blood pressure determinants in over  
1169 750,000 individuals. *Nat Genet* **51**, 51-62 (2019).
- 1170 109. Pulit, S.L. *et al.* Meta-analysis of genome-wide association studies for body fat  
1171 distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* **28**, 166-174  
1172 (2019).
- 1173 110. Teumer, A. *et al.* Genome-wide association meta-analyses and fine-mapping elucidate  
1174 pathways influencing albuminuria. *Nat Commun* **10**, 4130 (2019).
- 1175 111. Tin, A. *et al.* Target genes, variants, tissues and transcriptional pathways influencing  
1176 human serum urate levels. *Nat Genet* **51**, 1459-1474 (2019).
- 1177 112. Wuttke, M. *et al.* A catalog of genetic loci associated with kidney function from analyses  
1178 of a million individuals. *Nat Genet* **51**, 957-972 (2019).
- 1179 113. Astle, W.J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to  
1180 Common Complex Disease. *Cell* **167**, 1415-1429 e19 (2016).
- 1181 114. Guo, H. *et al.* Integration of disease association and eQTL data using a Bayesian  
1182 colocalisation approach highlights six candidate causal genes in immune-mediated  
1183 diseases. *Hum Mol Genet* **24**, 3305-13 (2015).
- 1184 115. Lambert, S.A. *et al.* The Human Transcription Factors. *Cell* **175**, 598-599 (2018).
- 1185 116. Garcia-Alonso, L., Holland, C.H., Ibrahim, M.M., Turei, D. & Saez-Rodriguez, J.  
1186 Benchmark and integration of resources for the estimation of human transcription  
1187 factor activities. *Genome Res* **29**, 1363-1375 (2019).

- 1188 117. Turei, D., Korcsmaros, T. & Saez-Rodriguez, J. OmniPath: guidelines and gateway for  
1189 literature-curated signaling pathway resources. *Nat Methods* **13**, 966-967 (2016).  
1190 118. Ceccarelli, F., Turei, D., Gabor, A. & Saez-Rodriguez, J. Bringing data from curated  
1191 pathway resources to Cytoscape with OmniPath. *Bioinformatics* **36**, 2632-2633 (2020).  
1192